THE MOLECULAR INVESTIGATION OF THE EFFECTS OF SIMVASTATIN, A CHOLESTEROL REDUCING DRUG, ON DIFFERENT RAT SKELETAL MUSCLE TISSUES

A THESIS SUBMITTED TO THE GRADUATE SCHOOL OF NATURAL AND APPLIED SCIENCES OF MIDDLE EAST TECHNICAL UNIVERSITY

BY

NİHAL ŞİMŞEK ÖZEK

IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF MASTER OF SCIENCE IN BIOLOGY

SEPTEMBER 2007
Approval of the Thesis:

THE MOLECULAR INVESTIGATION OF THE EFFECTS OF SIMVASTATIN, A CHOLESTEROL REDUCING DRUG, ON DIFFERENT RAT SKELETAL MUSCLE TISSUES

submitted by NİHAL ŞİMŞEK ÖZEK in partial fulfillment of the requirements for the degree of Master of Science in Biological Sciences Department, Middle East Technical University by,

Prof. Dr. Canan Özgen
Dean, Graduate School of Natural and Applied Sciences

Prof. Dr. Zeki Kaya
Head of Department, Biological Sciences

Prof. Dr. Feride SEVERCAN
Supervisor, Biological Sciences Dept., METU

Examinining Committee Members:

Assoc. Prof. Dr. Ewa Jakubowska Doğru
Biological Sciences Dept., METU

Prof. Dr. Feride Severcan
Biological Sciences Dept., METU

Assoc. Prof. Dr. Mehmet Dinçer Bilgin
Biophysics Dept., ADU

Assoc. Prof. Dr. Yıldırım Sara
Medical Pharmacology Dept., HU

Dr. Sreeparna Banerjee
Biological Sciences Dept., METU

Date: 07.09.2007
I hereby declare that all information in this document has been obtained and presented in accordance with academic rules and ethical conduct. I also declare that, as required by these rules and conduct, I have fully cited and referenced all material and results that are not original to this work.

Name, Last name : Nihal Şimşek Özек
Signature : 
ABSTRACT

THE MOLECULAR INVESTIGATION OF THE EFFECTS OF SIMVASTATIN, A CHOLESTEROL REDUCING DRUG, ON DIFFERENT RAT SKELETAL MUSCLE TISSUES

ŞİMŞEK ÖZEK, Nihal

M.Sc., Department of Biology
Supervisor: Prof. Dr. Feride SEVERCAN

September 2007, 125 pages

In the present study Fourier Transform Infrared (FTIR) and Attenuated Total Reflectance FTIR (ATR-FTIR) Spectroscopy were used to examine the effects of simvastatin on structure, composition and function of macromolecules of three different rat skeletal muscles EDL (Extensor Digitorium Longus), DIA (Diaphragm) and SOL (Soleus) containing different amount of slow and fast twitch fibers, at molecular level.

Simvastatin, a lipophilic statin, is widely used in the treatment of hypercholesterolemia and cardiovascular diseases due to its higher efficacy. However, long term usage of statins give rise to many adverse effects on different tissues and organs. Skeletal muscle accounts for around 45% of the total body weight and has a high metabolic rate and blood flow. As a consequence, it is highly exposed to drugs within the circulation. Therefore, it is one of the target tissues of statins. The two main types of muscle fibers are type I (slow-twitch) and type II (fast-twitch) fibers; having different structural
organization and metabolic features. EDL is a fast twitch muscle while SOL is slow twitch muscle. On the other hand, DIA shows intermediate properties between slow and fast twitch muscle.

The results of ATR-FTIR and FTIR spectra revealed a considerable decrease in protein and lipid content of simvastatin treated skeletal muscles, indicating protein breakdown or decreased protein synthesis and increased lipolysis. Moreover changes in protein structure and conformation were observed. In simvastatin treatment, muscle membrane lipids were more ordered and the amount of unsaturated lipids was decreased possibly due to lipid peroxidation. The drug treatment caused a decrease in the content of nucleic acids, especially RNA, and hydrogen and non-hydrogen bonded phospholipids in the membrane structures of skeletal muscles.

In all of the spectral parameters investigated EDL muscle was more severely affected from statin treatments while SOL was less affected from the drug treatments. Thus, FTIR and ATR-FTIR spectroscopy appear to be useful methods to evaluate the effects of statin on skeletal muscle tissues at molecular level.

Key words: ATR-FTIR spectroscopy, FTIR spectroscopy, statin, skeletal muscle, skeletal muscle fiber types
ÖZ

KOLESTEROL DÜŞÜRÜCÜ SİMVASTATİNİN FARKLI SIÇAN İSKELET KAS DOKULARI ÜZERİNDEKİ ETKİLERİİNİN MOLEKÜLER DÜZEYDE İNCELENMESİ

ŞİMŞEK ÖZEK, Nihal

Yüksek Lisans, Biyoloji Bölümü
Tez Yöneticisi: Prof. Dr. Feride Severcan

Eylül 2007, 125 sayfa

Bu çalışmada simvastatinin farklı oranlarda hızlı ve yavaş tıpte iskelet kası lifleri içeren siçan EDL, DIA ve SOL kasları üzerindeki etkisi Fourier Dönüşüm Kızılötesi ve Attenuated Total Reflektans Spektroskopisi (FTIR) ile moleküler düzeyde incelenmiştir.


İncelenen bütün spektral parametrelerden EDL kasının simvastatin tedavisinden daha çok etkilendiği, SOL kasının ise söz konusu ilaç tedavisinden minimum düzeyde etkilendiği bulunmuştur. Sonuç olarak, ATR-FTIR ve FTIR spektroskopisi teknikleri statinlerin iskelet kas dokuları üzerindeki etkilerini moleküler düzeyde incelemek için kullanılışı birer araç olarak görülmektedir.

Anahtar Kelimeler: ATR-FTIR spektroskopisi, FTIR spektroskopisi, statin, iskelet kası, iskelet kas lifi çeşitleri
To, my father, Yaşar, my daughter, Bilge and my husband, Ersin
ACKNOWLEDGEMENTS

I would like to thank my supervisor Prof. Dr. Feride SEVERCAN for her guidance, patience, encouragement and supervision throughout this thesis study.

I would also like to thank Prof. Dr. Rüştü ONUR and Assos. Prof. Dr. Yıldırım SARA for his suggestions and guidance with the animal studies.

I would like to express my thanks to all my thesis committee for their suggestions and criticism.

I also compassionately express my special thanks to Sevgi Görgülü owing to their precious help and lovely attitude in the course of experimental period and writing this thesis.

I would like to thank to my labmates, for their sincere friendship and supports.

I would like to send my ultimate appreciation to my father Yalçın Özek, my mother Emine Şimşek, Fatma Özek and my sister Fatma Şimşek for their endless patience, encouragement, support and love.
# TABLE OF CONTENTS

ABSTRACT ........................................................................................................ iv
ÖZ .................................................................................................................. vi
ACKNOWLEDGEMENTS ........................................................................ ix
TABLE OF CONTENTS .............................................................................. x
LIST OF FIGURES .................................................................................. xiii
LIST OF TABLES ..................................................................................... xvi
ABBREVIATIONS ....................................................................................... xviii

CHAPTER
1. INTRODUCTION ..................................................................................... 1

1.1 Skeletal Muscle ................................................................................... 1

1.1.1 Structural Organization of Skeletal Muscle .................................. 1
1.1.2 The Structure of Myofibrils.......................................................... 4
1.2 Skeletal Muscle Metabolism............................................................... 7
1.3 The Molecular Characteristics of Skeletal Muscle Fiber Types .......... 10
1.4 Statins and Simvastatin ........................................................................ 12

1.4.1 The Functions of Cholesterol ..................................................... 12
1.4.2 The Synthesis Cholesterol and Statins ......................................... 14
1.4.3 Pleiotropic Effects of Statins ....................................................... 20

1.4.3.1 Impact on Cardiovascular System ........................................ 21
1.4.3.2 Impact on Kidney ................................................................. 21
1.4.3.3 Impact on Central nervous system (CNS) diseases ........... 22
1.4.3.4 Impact on Autoimmune disease .......................................... 22
1.4.3.5 Impact on Bone Remodeling ............................................... 23
1.4.3.6 Impact on Gastrointestinal diseases ...................................... 23
1.4.4 Adverse Effects of Statins ............................................................ 23
1.4.5 Effects of Statins on Skeletal Muscles .......................................... 24
1.5 Spectroscopy ...................................................................................... 29
1.5.1 Infrared Spectroscopy ................................................................. 32
1.5.2 Fourier Transform Infrared Spectroscopy (FTIR) ............... 36
1.5.3 Attenuated Total Reflectance FTIR Spectroscopy .......... 38
1.5.4 The Advantages of FTIR and ATR-FTIR Spectroscopy ....... 40
1.6 Aim of the Study ........................................................................ 42

2. MATERIAL AND METHODS ................................................................. 44
2.1 Reagents ......................................................................................... 44
2.2 Preparation of Experimental Animals ........................................ 48
2.3 High Pressure Liquid Chromatography (HPLC) Studies .......... 48
2.4 Fourier Transform Infrared (FTIR) and Attenuated Total
Reflectance Fourier Transform Infrared (ATR-FTIR) Spectroscopic
Measurements............................................................................... 48
2.4.1 Sample Preparation for FT-IR and ATR-FTIR Studies ........ 48
2.4.2 FTIR and ATR-FTIR spectroscopy ........................................... 49
2.4.3 Cluster Analysis........................................................................ 51
2.5 Statistical Test .............................................................................. 52

3. RESULTS ........................................................................................... 53
3.1 Body Weights, Food, Drug Intake and Serum Cholesterol
Levels of Rats .................................................................................. 53
3.2 Infrared Spectroscopy Studies ...................................................... 55
3.2.1 General FTIR and ATR-FTIR Spectrum and Band
Assignment Skeletal Muscle Tissue ............................................. 55
3.2.2 Comparison of Spectra of Skeletal Muscle Fiber Types........ 59
3.2.2.1 Comparison of Control and Simvastatin EDL Skeletal
Muscle Fiber ................................................................................. 59
3.2.2.2 Comparison of Control and Simvastatin Treated DIA
Skeletal Muscle ............................................................................. 65
3.2.2.3 Comparison of Control and Simvastatin Treated SOL
Skeletal Muscle ............................................................................. 69
3.2.3 Numerical Comparisons of the Bands of Control and Simvastatin Treated Spectra of EDL, DIA and SOL Muscles .............................................................. 73

3.2.3.1 Comparisons of Control and Simvastatin Treated Spectra of EDL, DIA and SOL Muscles in the 3750-3025 cm\(^{-1}\) Region ......................................................... 73

3.2.3.2 Comparisons of Control and Simvastatin Treated Spectra of EDL, DIA and SOL Muscles in the 3025-2800 cm\(^{-1}\) Region ............................................................. 76

3.2.3.3 Comparison of Control and Simvastatin Treated Spectra of EDL, DIA and SOL Muscles in the 1850-850 cm\(^{-1}\) Region ................................................................. 83

4. DISCUSSION ........................................................................................................ 93

5. CONCLUSION .................................................................................................... 105

REFERENCES ..................................................................................................... 107
LIST OF FIGURES

Figure 1.1. The structural organization of skeletal muscle ............................................. 3
Figure 1.2. The arrangements of actin and myosin ............................................................. 5
Figure 1.3. Structure of sarcomer ................................................................................. 6
Figure 1.4. Skeletal Muscle Metabolism at resting, moderate and peak activity ................................. 9
Figure 1.5. Serial sections stained with ATPase type 1 fibers and the subdivision of type 2 fibers into 2A and 2B ............................................................ 12
Figure 1.6. The cholesterol biosynthesis pathway ........................................................... 15
Figure 1.7. Inhibition of HMG CoA reductase by statins ................................................ 16
Figure 1.8. The chemical structures of the hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors ................................................................. 18
Figure 1.9. The Pleiotropic effects of statins ................................................................. 20
Figure 1.10. Hypothetical Scheme of statin induced apoptosis ....................................... 29
Figure 1.11. Typical energy-level diagrams showing the ground state and the first excited state ........................................................................................................... 31
Figure 1.12. The Electromagnetic spectrum .................................................................. 33
Figure 1.13. Stretching and bending vibrations ............................................................. 35
Figure 1.14. Symmetric and asymmetric stretching vibrations ................................. 35
Figure 1.15. Types of bending vibrations ......................................................................... 35
Figure 1.16. Basic components of an FTIR spectrometer ............................................. 37
Figure 1.17. Schematic of a Michelson interferometer ................................................ 37
Figure 1.18. Schematic of a typical attenuated total reflectance cell .............................. 39
Figure 2.1 Oral gavage method .................................................................................... 45
Figure 2.2. Rat lateral surface of the tibia and the muscles of the left limb ......... 46
Figure 2.3. The dorsal and caudal surface of rat diaphragm ........................................ 47
Figure 2.4. The sample position on ATR-FTIR Spectroscopy ....................................... 50
Figure 3.1. Serum total cholesterol values in control and simvastatin treated animals ................................................................................................................. 54
Figure 3.2.A. The representative infrared spectra of control groups of EDL and SOL muscles in the 3850-850 cm\(^{-1}\) region ....................... 56

Figure 3.2.B. The representative infrared spectrum of control groups of Diaphragm muscle in the 3850-850 cm\(^{-1}\) region ....................... 57

Figure 3.3. The representative infrared spectra of control and simvastatin treated ED muscles in the 3750-3025 cm\(^{-1}\) region ....................... 60

Figure 3.4. The representative infrared spectra of control and simvastatin treated EDL muscles in the 3025-2800 cm\(^{-1}\) region ....................... 60

Figure 3.5. The representative infrared spectra of control and simvastatin treated EDL muscles in the 1850-850 cm\(^{-1}\) region ....................... 62

Figure 3.6. Hierarchical clustering of control and simvastatin treated EDL muscles using second derivative spectra.......................... 64

Figure 3.7. The representative infrared spectra of control and simvastatin treated EDL muscles in the 3750-3025 cm\(^{-1}\) region ....................... 66

Figure 3.8. The representative infrared spectra of control and simvastatin treated EDL muscles in the 3025-2800 cm\(^{-1}\) region ....................... 66

Figure 3.9. The representative infrared spectra of control and simvastatin treated DIA muscles in the 1800-850 cm\(^{-1}\) region ....................... 67

Figure 3.10. Hierarchical clustering of control and simvastatin treated DIA muscles using second derivative spectra......................... 68

Figure 3.11. The representative infrared spectra of control and simvastatin treated SOL muscles in the 3750-3025 cm\(^{-1}\) region ....................... 70

Figure 3.12. The representative infrared spectra of control and simvastatin treated SOL muscles in the 3025-2800 cm\(^{-1}\) region ....................... 70

Figure 3.13. The representative infrared spectra of control and simvastatin treated SOL muscles in the 1850-850 cm\(^{-1}\) region ....................... 71

Figure 3.14. Hierarchical clustering of control and simvastatin treated SOL muscles using second derivative spectra......................... 72

Figure 3.15. Comparison of Amide A band area for control and simvastatin treated groups of EDL, DIA and SOL muscles ....................... 74
Figure 3.16. Comparison of =CH olefinic band area for control and simvastatin treated groups of EDL, DIA and SOL muscles ......................... 77
Figure 3.17. Comparison of CH2 asymmetric band frequency value for control and simvastatin treated groups of EDL, DIA and SOL muscles. 81
Figure 3.18. Comparison of C=O Ester stretching band area value for control and simvastatin treated groups of EDL, DIA and SOL muscles. 86
Figure 3.19. Comparison of Amide I band area value for control and simvastatin treated groups of EDL, DIA and SOL muscles ....... 87
Figure 3.20. Comparison of Amide II band area value for control and simvastatin treated groups of EDL, DIA and SOL muscles ....... 87
Figure 3.21. Comparison of C=O stretching band area value for control and simvastatin treated groups of EDL, DIA and SOL muscles ....... 91
**LIST OF TABLES**

Table 1.1 Ultrastructural and cytochemical properties of skeletal muscle fibers .............................................................. 11

Table 1.2 Comparative efficacies of the different statins on various lipid fractions ........................................................................................................ 16

Table 1.3. Lipophilicity and pharmacokinetic parameters of statins on the market ......................................................................................................................... 19

Table 1.4. Mechanisms for direct vascular actions ........................................ 21

Table 1.5. Incidence rate of Rhabdomyolysis in statins................................. 26

Table 1.6. Materials used as ATR crystals and their properties...................... 40

Table 3.1. Food intake, water intake and body weight in rats treated with simvastatin ........................................................................................................... 54

Table 3.2. General band assignment of rat skeletal muscle ......................... 58

Table 3.3. The changes in the band area values of the control and simvastatin treated EDL, DIA and SOL spectra in 3750-3025 cm⁻¹ region...... 75

Table 3.4. The changes in the band frequency values of the control and simvastatin treated EDL, DIA and SOL spectra in 3750-3025 cm⁻¹ region ..................................................................................................................................... 75

Table 3.5. The changes in the band area values of the control and simvastatin treated EDL, DIA and SOL spectra in 3025-2800 cm⁻¹ region..... 78

Table 3.6. The changes in the band area values of the control and simvastatin treated EDL, DIA and SOL spectra in 3025-2800 cm⁻¹ region....... 79

Table 3.7. The changes in the lipid-to-protein ratio of bands for control and simvastatin treated EDL, DIA and SOL muscles ....................... 82

Table 3.8. The changes in the bandwidth values of the control and simvastatin treated EDL, DIA and SOL spectra for CH₂ asymmetric band .... 82

Table 3.9. The changes in the band area values of control and simvastatin treated EDL, DIA and SOL spectra in 1850-850 cm⁻¹ region...... 84
Table 3.10. The changes in the band frequency values of the control and simvastatin treated EDL, DIA and SOL spectra in 1850-850 cm\(^{-1}\) region .......................................................... 85

Table 3.11. The changes in the bandwidth values of the control and simvastatin treated EDL, DIA and SOL spectra for Amide I band ........................................................................................................... 88

Table 3.12. The changes in the DNA to protein ratio of the control and simvastatin treated EDL, DIA and SOL muscles ......................... 90
ABBREVIATIONS

FTIR  Fourier Transform Infrared Spectroscopy

ATR-FTIR  Attenuated Total Reflectance- Fourier Transform Infrared Spectroscopy

EDL  Extensor Digitorium Longgus

DIA  Diaphragm

SOL  Soleus
CHAPTER 1

INTRODUCTION

In this study the effects of Simvastatin on three types of skeletal muscles, namely Extensor Digitorum Longus (EDL), Diaphragm (DIA) and Soleus (SOL) were reported at molecular level via Fourier transform infrared (FTIR) and Attenuated Total Reflectance Fourier transform infrared (ATR-FTIR) spectroscopic techniques. In this chapter a detailed preliminary survey including statins, structural properties of skeletal muscle, types of skeletal muscles and their structural properties, the effects of statins on skeletal muscle tissue, and basis of infrared spectroscopy have been conducted.

1.1 Skeletal Muscle

Skeletal muscle is the largest tissue mass in the human body, representing about 40% to 45% of total body weight. The main function of skeletal muscle is to perform mechanical work at the expense of potential chemical energy, usually for movement. In addition, it is involved in many other physiological processes. For example, it is a key player in thermogenesis and as a metabolic organ, it is important in fuel and energy homeostasis. In order to achieve these functions, muscle has a very complex structure that is composed of several contractile components (Storey, 2004).

1.1.1 Structural Organization of Skeletal Muscle

Skeletal muscles are a discrete organ, made up of hundreds to thousands of muscle fibres or myofibers which are the most basic structural element of the
skeletal muscle. The structural organization of muscle and muscle fibers is shown in Figure 1.1. The entire muscle is surrounded by a fibrous connective tissue called epimysium. Groups of muscle fibers are arranged in bundles called fascicles, and are surrounded by a connective tissue sheath known as the perimysium. The perimysium contains blood vessels and nerves that maintain blood flow and innervate the fascicles. Within a fascicle, a fine layer of connective tissue, which further covers each muscle fiber and separates it from neighboring fibers, is called the endomysium. This connective tissue layer contains:

1- Capillary networks that supply oxygen and nutrients to individual muscle fibers.
2- Satellite cells, embryonic stem cells that function in the repair of the damaged muscle tissue
3- Nerve fibers that control the muscle.

Beneath the endomysium, each fiber is surrounded by the plasma membrane (sarcolemma) which has the properties of excitable cells and propagates action potentials. The sarcolemma contains proteins and strands of collagen. It makes thin tubular invaginations called transverse tubules (T-tubules) repeatedly found along the muscle cell and that deeply plunge into the center of the fiber. These T-tubules propagate action potentials throughout the muscle fiber, thereby causing muscle contraction. The cytoplasm of the muscle fiber, called sarcoplasm, contains organelles (required for its own functioning) and cytoskeleton. The sarcoplasm contains enzymes, fat and glycogen particles, nuclei, mitochondria and other organelles. Each myofiber contains a multitude of nuclei derived from myoblasts located at the periphery of the myofibers. In addition, separate cells called satellite cells are located between the basal lamina and plasma membrane and play a key role in the muscle regeneration process (Storey, 2004).
Water constitutes approximately 75% of skeletal muscle, and about 20% of skeletal mass is composed of proteins. Most abundant skeletal muscle proteins are myosin, actin, tropomyosin and troponin. Actin and myosin are contractile protein while the others are regulatory proteins in muscle contraction. In addition to the proteins directly involved in the contraction process, there are a number of other sarcomeric proteins which are thought to play distinct
physiological roles such as membrane stabilization, force transmission, and ion channel anchorage (Vigoreaux, 1994; Berthier and Blaineau, 1997). These are namely titin, nebulin, spectin, vinculin, talin, desmin, the muscle isoform of creatine kinase (CK), M protein, myomesin and skelemins. In addition, the oxygen binding protein, myoglobin, is also found in skeletal muscle tissue. The remaining 5% is composed of enzymes, salts, minerals, and other substances, including high-energy phosphates, urea, lactate, calcium, magnesium, phosphorous, sodium, potassium, chloride ions, amino acids, fats and carbohydrates (Greisheimer and Wiedeman, 1972; Shier et al., 1996).

1.1.2 The Structure of Myofibrils

Each skeletal muscle fiber contains hundreds to thousands of myofibrils. Myofibrils consist of myofilaments which are organized into repeating functional units called sarcomeres. A sarcomere contains (1) thick filaments, (2) thin filaments, (3) proteins that stabilize the positions of the thick and thin filaments, and (4) proteins that regulate the interactions between thick and thin filaments (Storey, 2004).

Differences in the size, density and distribution of thick and thin filaments account for the banded appearance of each myofibril (Figure 1.2 and 1.3). There are dark bands (A bands-anisotropic) and light bands (I bands-isotropic). The darker A bands are composed of thick myosin filaments and the lighter I bands are composed of the thin actin filaments. The thin dark line that bisects I bands and adheres to the sarcolemma is called as Z line, which gives stability to entire structure. The center of A bands contain the clear H zone or band, a region of lower optical density due to the absence of actin filaments. The M band bisects the central portion of the H band, which shows the center of the Z lines, consisting of protein structures that support the arrangement of the
myosin filaments (McArdle, Katch, Katch, 2001; Greisheimer and Wiedeman, 1972; Garrett et al., 1983).

**Figure 1.2.** The arrangements of actin and myosin (Martini, 2004).
The sliding filament model was proposed by Huxley and co-workers in 1950s. They hypothesized that muscle contraction resulted from filament movement due to elevated Ca²⁺ levels. In their theory, they describe how the thick and thin filaments slide past each other, causing the sarcomere to shorten. The overlap between myofilaments increases but their individual length remains constant. When muscles are relaxed, the sarcoplasmic Ca²⁺ levels are low and the tropomyosin in the thin filaments is disposed in such a way that the myosin binding site of actin is obstructed. Upon muscle stimulation, the myoplasmic Ca²⁺ levels increase, the released Ca²⁺ binds to troponin inducing a
conformational change that removes tropomyosin from the thin filament. Myosin can access its binding site on actin and the cross-bridges can form.

Myosin hydrolyzes ATP to ADP and inorganic phosphate. As a consequence, myosin in high-energy state changes its conformation and myosin heads bind to and rotate against actin filaments resulting in shortening of the fibers. Therefore contraction occurs. As Ca\(^{2+}\) levels lower during muscle relaxation, Ca\(^{2+}\) detach from the troponin complex, which in turn blocks tropomyosin and the myofilaments slide back to the resting configuration and then contraction stops (Martini, 2004).

1.2. Skeletal Muscle Metabolism

The skeletal muscles are able to use fatty acids, carbohydrates, ketone bodies and some amino acids as substrates to fulfill their energy requirements during rest and exercise (Newholme & Leech 1990). Under normal conditions, fatty acids and glucose are quantitatively the most important oxidizable substrates for muscle cells.

Glucose from glycogen in the liver has to be transported by the blood and taken up by the muscle before it can undergo glycolysis and be released as lactate, alanine or pyruvate, or be oxidized in the Krebs cycle. Glycogen stored in the skeletal muscle can undergo glycogenolysis, and hence directly glycolysis, and used for fuel in contractile processes.

Lipids are the predominant fuel at rest in the post absorptive and fasted state when the muscle glucose utilization is low. The capacity of the muscle fibers to synthesize fatty acid (FA) de novo is limited. However, over 50 % of the energy requirement of resting muscle is derived from their oxidation and thus, FAs have to be supplied first from extracellular sources. Fat is made available to the skeletal muscle cells via the blood as plasma nonesterified FAs or as
triacylglycerols (TGs) that form the lipid core of circulating TG-rich lipoproteins, very-low-density lipoprotein (VLDL) and chylomicrons (CM). Nonesterified FAs are liberated from the adipose tissue TG storage after lipolysis. From TG-rich lipoproteins, FAs are made available to the skeletal muscle after hydrolysis by enzyme lipoprotein lipase (LPL). This enzyme is attached to the luminal surface of the endothelial cells in the capillary bed of the skeletal muscle (Braun and Severson 1992).

A resting muscle breaks down exogenous fatty acids entering the cell. At moderate levels of activity, muscle breaks down the fatty acids and glucose through aerobic metabolism. Glucose is obtained from glycogen in the muscle. If glycogen reserves are low, the muscle fiber can also break down other substrates, such as lipid or amino acids. However, at the peak levels, most of ATP are obtained from glycolysis. Fatty acid oxidation now provides only about one-third of the ATP consumed (Figure 1.4) (Martini, 2004).
Figure 1.4. Skeletal Muscle Metabolism at resting (a), moderate (b) and peak (c) activity (Martini, 2004).
1.3 The Molecular Characteristics of Skeletal Muscle Fiber Types

Due to the various natures of movement, different muscle types are required to carry out different functional tasks. Muscle can be grouped into two main categories according to the functional and metabolic characteristics (Table 1.1) (Okumura et al., 2005)

1. Slow twitch (Type I) Fibers
2. Fast twitch (Type II) Fibers

These fibers can be distinguished easily by special stains for specific enzymes, enzymes that take role in oxidative or glycolytic metabolism of fuels inside skeletal muscle structure. An example of the determination of skeletal muscle fiber types by staining ATPase was shown in Figure 1.5.

Slow twitch or type I fibers are red fibers due to the high myoglobin content and they are identified by a slow contraction time and a high resistance to fatigue. They have a small fiber diameter, a high mitochondrial and capillary density. They also contain many of the enzymes involved in the oxidative pathways (Krebs cycle, electron transport chain). Functionally, these fibers are used for aerobic activities requiring low force production, such as walking and maintaining posture (Storey, 2004).

Fast twitch or type II fibers have white fibers low myoglobin content and therefore it is known as white fibers. They are identified by a fast contraction time and a low resistance to fatigue. The fast twitch fibers can be divided into two groups: fast oxidative and fast glycolytic fibers. Fast oxidative/type IIa, fibers have a faster contraction speed than type I, but they still tend to be high in oxidative enzymes and ATPase activity and fatigue less quickly than other type II fibers. Fast glycolytic/type IIb fibers contract at a very quick rate and produce extremely large forces, but cannot maintain these tensions for more
than a few contractions without rest. These properties correlate with high ATPase and glycolytic activities and low oxidative capacity (Lieber, 2002).

Table 1.1 Ultrastructural and cytochemical properties of skeletal muscle fibers (Storey, 2004).

<table>
<thead>
<tr>
<th>Fiber Type</th>
<th>Characteristic</th>
<th>Type I</th>
<th>Type II A</th>
<th>Type II B/X</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physiology</td>
<td>Contraction Velocity</td>
<td>Slow</td>
<td>Fast</td>
<td>Fast</td>
</tr>
<tr>
<td></td>
<td>Myosin ATPase (duration)</td>
<td>Slow</td>
<td>Fast</td>
<td>Fast</td>
</tr>
<tr>
<td></td>
<td>Ca²⁺ reuptake</td>
<td>Slow</td>
<td>Fast</td>
<td>Fast</td>
</tr>
<tr>
<td></td>
<td>Fatigue resistant</td>
<td>+++</td>
<td>++</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>Recruitment order</td>
<td>Early</td>
<td>Mid</td>
<td>Late</td>
</tr>
<tr>
<td>Enzyme Activities</td>
<td>Myosin ATPase</td>
<td>+</td>
<td>++</td>
<td>+++</td>
</tr>
<tr>
<td></td>
<td>Hexokinase</td>
<td>+++</td>
<td>++</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>Glycogen Phosphorylase</td>
<td>+</td>
<td>++</td>
<td>+++</td>
</tr>
<tr>
<td></td>
<td>Glycolytic enzymes (α-Glycerophosphate Dehydrogenase)</td>
<td>+</td>
<td>++</td>
<td>+++</td>
</tr>
<tr>
<td></td>
<td>Oxidative Enzymes (Succinate Dehydrogenase)</td>
<td>+++</td>
<td>++</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>Myoglobin</td>
<td>+++</td>
<td>++</td>
<td>+</td>
</tr>
<tr>
<td>Morphology</td>
<td>Color</td>
<td>Red</td>
<td>Red</td>
<td>White</td>
</tr>
<tr>
<td></td>
<td>Fiber diameter</td>
<td>+</td>
<td>+++</td>
<td>++++</td>
</tr>
<tr>
<td></td>
<td>Capillary density</td>
<td>+++</td>
<td>++</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>Mitochondrial density</td>
<td>+++</td>
<td>+++</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>Z line thickness</td>
<td>+++</td>
<td>++</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>Sarcoplasmic reticulum volume</td>
<td>+</td>
<td>+++</td>
<td>+++</td>
</tr>
<tr>
<td></td>
<td>T tubules volume</td>
<td>-</td>
<td>+++</td>
<td>+++</td>
</tr>
<tr>
<td></td>
<td>Motor-end-plate area</td>
<td>+</td>
<td>+++</td>
<td>+++</td>
</tr>
<tr>
<td>Metabolites</td>
<td>Glycogen</td>
<td>++</td>
<td>++</td>
<td>+++</td>
</tr>
<tr>
<td></td>
<td>Triglycerides</td>
<td>+++</td>
<td>++</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>Antibodies to fast myosin heavy chain</td>
<td>-</td>
<td>+++</td>
<td>+++</td>
</tr>
<tr>
<td></td>
<td>Antibodies to slow myosin heavy chain</td>
<td>+++</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>
Figure 1.5. Serial sections stained with (a) ATPase pH 9.4 and following preincubation at (b) pH 4.6 and (c) pH 4.3 showing a checkerboard pattern of type 1 fibers and the subdivision of type 2 fibers into 2A and 2B (Dubowitz., 2006)

1.4 Statins and Simvastatin

1.4.1 The Functions of Cholesterol

Cholesterol is a vital building block molecule of life in many ways as given below.

1- It regulates the fluidity of cell membranes, preventing them from becoming both too rigid and too fluid and helps maintain the integrity of these membranes. It is also a primary component of lipid rafts, where it helps secure proteins involved in cell signaling (Alberts et al., 2002).

2- It supports of the nervous system. It is a vital component of the myelin sheath, which allows neurons to conduct impulses necessary to communicate with each other, and has been found to be the rate-limiting factor in the formation of synapses, the formation of which is necessary for learning and the formation of memories. Cholesterol not only helps guide
the connecting parts of neurons to the right places, but also is necessary for their ability to grow in the first place (Bittman, 1997).

3- Cholesterol, more precisely 7-dehydrocholesterol, is the precursor to vitamin D. Vitamin D has long been recognized for its role in maintaining calcium balance and promoting bone health, but is more recently becoming known for a wide range of other functions, including the maintenance of mental health, a strong immune system, blood sugar regulation, and the prevention of cancer.

4- Cholesterol is also the precursor to all steroid hormones, including mineralocorticoids, glucocorticoids, and sex hormones. This makes all of the following important functions of cholesterol; athletic performance, regulating blood sugar, controlling blood pressure, regulating mineral balance, maintaining libido, building muscle mass (Harvey et al., 2005).

5- It has a role in digestion. It is to be used by the liver to synthesize bile acids. Bile acids are secreted into the intestines where they are used to mix fats with the water-soluble enzymes that digest them (Harvey et al., 2005).

On the other hand, high levels of this lipophilic substance lead to atherosclerosis, a predisposing factor to the development of coronary artery disease. Atherosclerosis involves an accumulation of cholesterol esters and other blood lipids and lipoproteins in macrophage cells found in the intima of arteries. This type of diseases involves one or more specific cardiovascular pathologies, including myocardial infarction, ischemia, and angina (Roche, 2005).
1.4.2 The Synthesis Cholesterol and Statins

Cholesterol is synthesized in all types of cells but primarily in liver cells from the two-carbon acetate group of acetyl-CoA. Acetyl-CoAs are converted to 3-hydroxy-3-methyl glutaryl-CoA (HMG-CoA) and this is converted to mevalonate. The conversion of HMG CoA to mevalonate is catalyzed by HMG-CoA reductase (HMGR) enzyme. Statins inhibits this enzyme and therefore it is named as HMG-CoA reductase inhibitors (Figure 1.6). HMGR enzyme consists of a single polypeptide chain of 888 amino acids (Istvan et al., 2000a; 2000b). The amino terminal 339 residues are membrane bound and reside in the endoplasmic reticulum membrane while the catalytic activity of protein resides in its cytoplasmic, soluble C-terminal region portion (residues 460-888). A linker region (residues 340-459) connects the two portions of the protein. The three dimensional structure of catalytic portion of the HMGR shows a close association of two monomers in a dimer and of two dimmers in a tetramer. Statins consist of HMG-like moieties and different largely hydrophobic attachments. HMG-like moiety may be present in an active lactone form and it may occupy the HMG-binding pocket, thereby blocking HMG-CoA’s access to human HMG-CoA reductase. HMG-CoA reductase catalyzes the 4-electron reduction of HMG-CoA into CoA and mevalonate, a cholesterol precursor, with oxidation of two molecules NADPH (Figure 1.7). Statins target hepatocytes and inhibit the conversion of HMG-CoA to mevalonate, thus inhibiting an early step of the cholesterol biosynthetic pathway. The induction of a conformation change of HMG-CoA reductase in the active site makes the statins very specific and effective. The inhibition of the HMG-CoA reductase results in the activation of a protease which slices the sterol regulatory element binding proteins (SREBPs) from the endoplasmic reticulum. SREBPs are translocated at the level of the nucleus, where they increase the gene expression for LDL receptor. This has an influence on the reduction of circulating low density lipoproteins and its precursors.
(intermediate density and very low density lipoproteins). As a consequence, low density lipoproteins and its precursors are cleared from the circulation (Goldstein and Brown, 1990). Furthermore, statins treatment lower triglyceride levels (5% to 10%) and raise the plasma concentration of anti-atherogenic high-density lipoproteins (HDL). On the other hand, statins have differences in the ability to decrease or increase in these parameters explained above. These differences were given in Table 1.2 (Ginsberg et al., 1987; Vega et al., 1998; Bakker-Arkema et al., 1996; Grundy 1998; Brown et al., 1998; Brown and Goldstein, 2004).

**Figure 1.6.** The cholesterol biosynthesis pathway
(http://goldbamboo.com/topic-t1183-a1-6Cholesterol.html)
Figure 1.7. Inhibition of HMG CoA reductase by statins (Tchapda, 2005).

Table 1.2 Comparative efficacies of the different statins on various lipid fractions.

(% Serum LDL-C reduction, Serum HDL-C increase, Serum triglyceride reduction) . LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol, ATV-Atorvastain, CER-Cerivastatin, FLU-Fluvastatin, LOV-Lovastatin, PRA-Pravastatin, SIM-Simvastatin (Schachter, 2005)

<table>
<thead>
<tr>
<th></th>
<th>ATV 40 mg/day</th>
<th>CER 0.3 mg/day</th>
<th>FLU 40 mg/day</th>
<th>LOV 40 mg/day</th>
<th>PRA 40 mg/day</th>
<th>SIM 40 mg/day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum LDL-C reduction (%)</td>
<td>50</td>
<td>28</td>
<td>24</td>
<td>34</td>
<td>34</td>
<td>41</td>
</tr>
<tr>
<td>Serum HDL-C increase (%)</td>
<td>6</td>
<td>10</td>
<td>8</td>
<td>9</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td>Serum triglyceride reduction (%)</td>
<td>29</td>
<td>13</td>
<td>10</td>
<td>16</td>
<td>24</td>
<td>18</td>
</tr>
</tbody>
</table>
Statins can be divided into two groups:

1- Non synthetic statins: They are obtained by fermentation. Pravastatin, Lovastatin and Simvastatin
   For example, simvastatin is obtained from a chemical alteration of fungal products.
2- Synthetic statins: Atorvastatin, fluvastatin, cerivastatin and rosvuavastatin.

Lovastatin and Simvastatin occur in an inactive closed lactones ring form. They are enzymatically hydrolyzed to their active hydroxyl acid forms in the liver. The others statins are administered as an active compound (acid form). The statins have rigid, hydrophobic groups that are covalently linked to the HMG-like moiety. Lovastatin, pravastain and simvastatin posses a hydroxy-hexahydro naphthalene ring system, to which different side chains are linked at C8 and C6. However synthetic statins have larger groups linked to the HMG-like moiety. These groups range in the character from very hydrophobic to partly hydrophobic (Shitara and Sugiyama, 2006). The chemical structure of statins is shown in Figure 1.8.

Although chemically related, statins differ in their physicochemical and pharmacokinetic properties (Table 1.3). Among available HMG-CoA reductase inhibitors, there are pharmacokinetic differences in distribution, half-lives, systemic exposure, maximum concentrations, bioavailability, protein binding, metabolic pathways, the presence of active metabolites and excretion routes, strictly related to their physicochemical and biochemical properties, which in turn may translate into differences in long-term safety (Garcia et al., 2003, Schachter, 2005).
Figure 1.8 The chemical structures of the hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (Shitara and Sugiyama, 2006).
Table 1.3 Lipophilicity and pharmacokinetic parameters of statins on the market. NA* : non available, ATV-Atorvastain, CER-Cerivastatin, FLU-Fluvastatin, LOV-Lovastatin, PRA-Pravastatin, SIM-Simvastatin

<table>
<thead>
<tr>
<th>Parameter</th>
<th>ATV</th>
<th>CER</th>
<th>FLU</th>
<th>LOV</th>
<th>PRA</th>
<th>SIM</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Absorption</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fraction absorbed (%)</td>
<td>30</td>
<td>98</td>
<td>98</td>
<td>30</td>
<td>34</td>
<td>60-80</td>
</tr>
<tr>
<td>T&lt;sub&gt;max&lt;/sub&gt; (hr)</td>
<td>2-</td>
<td>2.5</td>
<td>0.5-1</td>
<td>2-4</td>
<td>0.9-1.6</td>
<td>1.3-2.4</td>
</tr>
<tr>
<td>C&lt;sub&gt;max&lt;/sub&gt; (ng/mL)</td>
<td>27-66</td>
<td>2</td>
<td>448</td>
<td>10-20</td>
<td>45-55</td>
<td>10-34</td>
</tr>
<tr>
<td>Bioavailability</td>
<td>12</td>
<td>60</td>
<td>19-29</td>
<td>5</td>
<td>18</td>
<td>5</td>
</tr>
<tr>
<td>% Effect of food</td>
<td>↓13%</td>
<td>0</td>
<td>↓15% to ↑ 25%</td>
<td>↑ 50%</td>
<td>↓30%</td>
<td>0</td>
</tr>
<tr>
<td><strong>Distribution</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fraction absorbed (%)</td>
<td>80-90</td>
<td>&gt;99</td>
<td>&gt;99</td>
<td>&gt;95</td>
<td>43-55</td>
<td>94-98</td>
</tr>
<tr>
<td>Lipophilicity, (log P)</td>
<td>4.06</td>
<td>1.47</td>
<td>3.24</td>
<td>4.27</td>
<td>-0.22</td>
<td>4.68</td>
</tr>
<tr>
<td><strong>Metabolism</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatic metabolism</td>
<td>CYP3A4</td>
<td>CYP3A4/2 C8</td>
<td>CYP2C9</td>
<td>CYP3A4</td>
<td>Sulfation</td>
<td>CYP3A4</td>
</tr>
<tr>
<td>Clearance (L/hr/kg)</td>
<td>0.25</td>
<td>0.20</td>
<td>0.97</td>
<td>0.26-1.1</td>
<td>0.81</td>
<td>0.45</td>
</tr>
<tr>
<td>Mainly cleared as</td>
<td>Metabolites</td>
<td>Metabolites</td>
<td>Metabolites</td>
<td>Metabolites</td>
<td>Metabolites</td>
<td>Metabolites</td>
</tr>
<tr>
<td>Hepatic extraction (%)</td>
<td>&gt;70</td>
<td>NA*</td>
<td>&gt;68</td>
<td>&gt;70</td>
<td>46-66</td>
<td>78-87</td>
</tr>
<tr>
<td>Systemic metabolites</td>
<td>Active</td>
<td>Active</td>
<td>Inactive</td>
<td>Active</td>
<td>Inactive</td>
<td>Active</td>
</tr>
<tr>
<td><strong>Excretion</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>t&lt;sub&gt;1/2&lt;/sub&gt; (hr)</td>
<td>15-30</td>
<td>2.1-3.1</td>
<td>0.5-2.3</td>
<td>2.9</td>
<td>1.3-2.8</td>
<td>2-3</td>
</tr>
<tr>
<td>Urinary excretion (%)</td>
<td>Negligible</td>
<td>30</td>
<td>6</td>
<td>10</td>
<td>20</td>
<td>13</td>
</tr>
<tr>
<td>Fecal excretion (%)</td>
<td>Major route</td>
<td>70</td>
<td>90</td>
<td>83</td>
<td>71</td>
<td>58</td>
</tr>
<tr>
<td>Other parameters</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prodrug</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Max. dose (mg/day)</td>
<td>80</td>
<td>0.8</td>
<td>40</td>
<td>80</td>
<td>40</td>
<td>80</td>
</tr>
</tbody>
</table>
1.4.3 Pleiotropic Effects of Statins

Pleiotropic effects of a drug are actions other than those for which the agent was specifically developed. These effects may be related or unrelated to the primary mechanism of action of the drug, and they are usually unanticipated. Pleiotropic effects may be undesirable (such as side effects or toxicity), neutral, or, as is especially the case with HMG-CoA reductase inhibitors (statins), beneficial. The general pleiotropic effects of statin were shown in Figure 1.9 (Paul and Gahtan, 2003).

Figure 1.9. The pleiotropic effects of statins. The important clinical, cellular, and molecular systems influenced by this class of drugs are represented. VSMC = vascular smooth muscle cell; MCP-1 = monocyte chemoattractant protein-1; MI = myocardial infarction; VCAM-1 = vascular cell adhesion molecule-1; TSP-1 = thrombospondin-1; CRP = C-reactive protein; IL-6 = interleukin-6; PDGF = platelet-derived growth factor; IL-8 = interleukin-8; DNA = deoxyribonucleic acid (Paul and Gahtan, 2003).
1.4.3.1. Impact on Cardiovascular System

Statins directly prevent atherosclerosis and cardiovascular diseases by inhibition of cholesterol biosynthesis associated with the inhibition of HMG-CoA reductase. However, statins also prevent cardiovascular diseases by other mechanisms which are related to the pleiotropic effects of statins (Corsini et al., 1999). The general mechanisms for direct vascular actions of statins are given in Table 1.4.

Table 1.4. Mechanisms for direct vascular actions (Shitara and Sugiyama, 2006)

<table>
<thead>
<tr>
<th>Lipid effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inhibition of cholesterol biosynthesis; Increased uptake and degradation of LDL</td>
</tr>
<tr>
<td>Inhibition of LDL oxidation</td>
</tr>
<tr>
<td>Inhibition of lipoprotein secretion</td>
</tr>
<tr>
<td>Inhibition of modified LDL endocytosis</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Antiatherosclerotic effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inhibition of migration and proliferation of arterial myocytes</td>
</tr>
<tr>
<td>Inhibition of macrophage growth</td>
</tr>
<tr>
<td>Inhibition of cholesterol accumulation in macrophages</td>
</tr>
<tr>
<td>Inhibition of cell adhesion</td>
</tr>
<tr>
<td>Inhibition of tissue factor expression and activity</td>
</tr>
<tr>
<td>Inhibition of superoxide generation</td>
</tr>
<tr>
<td>Inhibition of endothelin-1 synthesis and expression; Increased expression and activity of eNOS; Increased fibrinolytic activity</td>
</tr>
<tr>
<td>Induction of myocytes apoptosis in proliferative lesions</td>
</tr>
</tbody>
</table>

1.4.3.2. Impact on Kidney

The potential to ameliorate the impact of diabetes and to slow the progression of end stage renal disease are among the most promising roles for statins in the field of nephrology. Renal injury initiates inflammatory cascades that involve similar cellular events as seen in vascular tissue. Statins inhibit key events in this process that alter the progression of renal injury. Usui et al. (2003)
demonstrated a decrease in glomerular hypertrophy and albuminuria with cerivastatin treatment. One potential mechanism for this benefit was that cerivastatin inhibited leukocyte adhesion molecule expression on the glomerular endothelial cells, hence decreasing macrophage migration into the glomeruli (Almuti et al., 2006). Statins have also been reported to attenuate renal injury after an ischemic event.

1.4.3.3. Impact on Central Nervous System (CNS).

Statins have shown promise in the prevention of ischemic stroke in patients with coronary artery disease. Furthermore, some of the beneficial CNS effects of statins may be due to their augmentation of NO production as NO may improve CNS collateral blood flow, enhance cerebral vasodilator responses and prevent apoptosis (Del Zoppo, 1998).

In Alzheimer's disease (AD), elevated CNS cholesterol levels are thought to accelerate the cleavage of amyloid precursor protein (APP) to beta-amyloid (Aβ), a compound considered cytotoxic to oligodendrocytes and neurons. It has been found that the administration of simvastatin for a 6-month period to normo-cholesterolemic patients with mild AD decreased CNS Aβ levels (Fassbender et al., 2002; Locatelli et al., 2002).

1.4.3.4. Impact on Autoimmune System

Statins may have beneficial effects on autoimmune diseases such as rheumatoid arthritis, diabetes mellitus, psoriasis and inflammatory bowel disease. Modulation of T lymphocyte proliferation, differentiation and activation appears to be the primary mechanism (Almuti et al., 2006).

For instance, statins was found to decrease inhibit the expression of major histocompatibility antigen complex-II (MHC-II) on human macrophages and endothelial cells. Macrophages are thought to express MHC-II when they are activated. This allows them to activate T cells that, in turn, contribute to the
inflammatory process. This inhibition leads to a reduction of T cell proliferation and differentiation and subsequently to a reduction in the release of pro-inflammatory cytokines (Kwak et al., 2000).

1.4.3.5 Impact on Bone

Statins have positive and negative effects on bone. Their negative effect is the inhibition of bone resorption. It has been found that murine osteoclast formation in cultures was inhibited by both lovastatin and alendronate (a nitrogen-containing bisphosphonate). On the other hand, they stimulate bone formation. Statins was found to increase the number of osteoblasts and the amount of new bone formation in mouse skull bones (Mcfarlane et al., 2002).

1.4.3.6 Impact on Gastrointestinal System

Statins may decrease the incidence of colon cancer. Lovastatin, in combination with the chemotherapeutic agents 5-FU (5-fluorouracil) and cisplatin, was found to increase apoptosis and to decrease the proliferation of cells in colon cancer cell lines, thereby inhibiting the progression of the disease. Furthermore, the addition of statins to the therapeutic regimen allowed for the use of lower doses of chemotherapeutic drugs resulting in milder side effects (Sacks et al., 1996; Pedersen et al., 1996)

1.4.4 Adverse Effects of Statins

It has been reported that statins have many adverse effects of organs and tissues (Kiortsis et al., 2006). These adverse effects are given below:

- Gastrointestinal side effects: Nausea, dyspepsia, abdominal pain, flatulence and diarrhoea or constipation
- Skin side effects: Alopecia, rash, cheilitis, lichenoid eruption, dermographism, chronic urticaria and toxic epidermic necrolysis
- Sensory organs: Cataract formation, ocular hemorrhage, nasal polyposis
Central nervous system: Increase of suicides and violent deaths, depression, sleep disturbances, nightmares, headache, cognitive and memory problems.

Peripheral Nervous system: Idiopathic polyneuropathy

Renal effects: Proteinuria

Autoimmune disorders: lupus erythematosus, arthralgia dermatomyositis, polymyositis, autoimmune hepatitis

Erectile dysfunction, gynecomastia

Hepato-toxicity

1.4.5. Effects of Statins on Skeletal Muscles

Even though statins are used very successfully clinically and well tolerated, some adverse effects may also arise in skeletal muscle. These effects may range from myalgia, myopathy to potentially life-threatening rhabdomyolysis.

There are two reasons why skeletal muscle is primarily and profoundly affected tissue in the body from statin treatment. The first reason is that skeletal muscle is one of the lowest cholesterol biosynthetic tissues in body (Yokoyama et al., 2007). The second one is that skeletal muscle accounts for the around 45% of total weight and has a high metabolic rate and blood flow. As a consequence, it is highly exposed to drugs within the circulation (Evans and Rees, 2002A, 2002 B).

Myalgia and myopathy are characterized by diffuse muscle pain, tenderness, weakness associated with abnormal elevations in creatine kinase levels (< 10 times the upper limit of normal). Rhabdomyolysis is characterized by severe muscle destruction resulting in myoglobinuria and clinical features of muscle weakness, pain, swelling and cramps. This syndrome is the most harmful myotoxic effect of statin since it may cause death as a result of acute renal
failure. The incidence of these myotoxicities depends on several factors given below (Rosenson, 2004):

- The dosage of statin which is used
- The usage of statin with other drugs i.e. monotheraphy or polytheraphy
- The hydrophilic or lipophilic properties of statin drugs.

While the dose of drugs increases, the incidence of myotoxic effects raises. It has been shown a dose-dependent myotoxicity with simvastatin in both rats and humans. For example, the incidence of myopathy with patients receiving 20 mg simvastatin/d was found 0.04 % while this rate was observed 0.4 % in patients receiving 40 or 80 mg simvastatin/d (de Lemos et al., 2004).

The usage of statin with other drugs such as cyclosporin, fibrate and gemfibrozil at the same time increases the rate of occurrence of myotoxic effects since these drugs inhibits CYP enzyme system and leads to increased bioavailability of statins, thereby increasing the potential for myotoxicity (Evans and Rees, 2002).

The lipophilic or hydrophilic properties of statins also affect the incidence of the adverse effects in skeletal muscle since the lipophilic statins enter the cell by simple diffusion especially in unhepatic tissues. It has been shown that pravastatin is less myotoxic than simvastatin or lovastatin due to the its hydrophilicity, thus lower uptake of by myocytes (Masters et al., 1995). The incidence of rhabdomyolysis in different statin drugs was given in Table 1.5. (Cziraky et al., 2006).
Table 1.5 Incidence rate of Rhabdomyolysis in statins (Managed care claims database-USA) (Cziraky et al., 2006).

<table>
<thead>
<tr>
<th>Drug</th>
<th>Patient-Years</th>
<th>Incidence Rates (per 10,000 person-years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atorvastatin</td>
<td>261,567</td>
<td>2.4 (1.9-3.1)</td>
</tr>
<tr>
<td>Fluvastatin</td>
<td>12,635</td>
<td>1.6 (0.2-5.7)</td>
</tr>
<tr>
<td>Lovastatin</td>
<td>26,122</td>
<td>2.3 (0.8-4.5)</td>
</tr>
<tr>
<td>Pravastatin</td>
<td>64,254</td>
<td>3.4 (2.1-5.2)</td>
</tr>
<tr>
<td>Rosuvastatin</td>
<td>8,213</td>
<td>2.4 (0.3-8.8)</td>
</tr>
<tr>
<td>Simvastatin</td>
<td>54,394</td>
<td>3.5 (2.1-5.6)</td>
</tr>
<tr>
<td>Cerivastatin</td>
<td>4,719</td>
<td>10.6 (3.4-24.7)</td>
</tr>
</tbody>
</table>

The sensitivities of skeletal muscle fibers to statin are different. These differences result from the metabolic and structural differences in the slow and fast twitch muscle. Histological experiments show that fast twitch fibers are ultimately affected from statin treatment. It has been indicated that the fibers show a necrotic response to statin administration and this response increases along with glycolytic metabolic nature of muscle fibers as decreases with oxidative metabolic properties of fibers. Least sensitive → I < IIA < IID < IIB → Most sensitive (Westwood et al. 2005).

There are many histological, biochemical, physiological and some genetic studies to explain statin-induced myotoxicity in animals and humans.

Histological studies about statin induced myotoxicity revealed that they induce
- myofiber necrosis with interstitial edema (Smith et al., 1991)
- inflammatory cell infiltration (Smith et al., 1991)
- mitochondrial myopathy (England et al. 1995)
- disruption of sarcomere (Schaefer et al., 2004)
- T-tubular injury (Draeger et al., 2006)
Physiological studies showed that statins induce:

- Decrease in membrane chloride conductance (Pierno et al., 1995)
- Decrease in action potential amplitude (Pierno et al., 1999)
- Decrease Na\(^+\) channel function (Gray et al., 2000)
- Reduced flux through ATP-sensitive K\(^+\) channel (Pierno et al., 1992)
- Decrease Na\(^+\)-K\(^+\) ATPase density (Gray et al., 2000)
- Increase in sarcolemmal excitability (Pierno et al., 2006)
- Decrease in threshold value (Pierno et al., 2006)
- Increase in latency of the first action potential (Pierno et al., 2006, Pierno et al., 1995)
- Increase in Ca\(^{2+}\) release to sarcoplasm (Inoue et al., 2003; Sirvent et al., 2005; Liantonio et al., 2007)

Biochemical studies clarified that these drugs leads to:

- Increase (Phillips et al., 2002; Paiva et al., 2005) or no change (Yokoyama et al., 2007) in the level of tissue lipids
- Decrease in the level of tissue proteins (Master et al., 1995)
- Decrease in the level of tissue and mitochondrial DNA (Schick et al., 2007)

Genetic studies revealed that statins cause:

- Upregulation of genes which are responsible for protein degradation (Urso et al., 2005)
- Genetic abnormalities (Vladutiu et al., 2006)

Based on these studies, three theories about the mechanisms of statin induced myotoxicity has been proposed.
**THEORY 1:** Blocking cholesterol synthesis by statins reduces cholesterol content of skeletal muscle membranes and this makes them unstable.

As a result of cholesterol reduction, the membrane fluidity, its electrical properties and the functions of ion channel in membrane change. These changes affect the muscle cell functions.

**THEORY 2:** Statins lead to a reduced synthesis of ubiquinone (coenzyme Q10), an essential element of mitochondria, thereby disturbing normal cell respiration and energy production.

Ubiquinone (coenzyme Q10) is an essential cofactor of electron transport chain where ATP is generated. In addition, it serves as an important antioxidant in both mitochondria and lipid membranes and decreases oxidative DNA damage in human lymphocytes. The inhibition of cholesterol synthesis decreases the synthesis of precursors of ubiquinone. This leads to the impairment energy metabolism and increase in the amount of reactive oxygen species (Baker and Tarnopolsky, 2001)

**THEORY 3:** Reduction of small GTP-binding proteins leads to muscle apoptosis.

Cholesterol biosynthesis pathway is also known as mevalonate pathway. The intermediate products of this pathway are important for regulations of many cellular functions. Mevalonic acid, the synthesis of which is inhibited by statins, is a precursor of not only cholesterol but other metabolites including isopentyl adenosine contained in transfer RNA, dolichols for the synthesis of glycoproteins and CoQ_{10}. In addition, metabolites of mevalonic acid including farnesyl pyrophosphate and geranylgeranylpyrophosphate mediate the prenylation of some specific proteins. Prenylated proteins are involved in a
number of processes, including cell signal transduction, differentiation, proliferation, and myelination and cytoskeletal dynamics. The inhibition of cholesterol synthesis reduces the synthesis of the intermediary products, thereby inhibiting protein prenylation and stopping the cellular growth and functions i.e. apoptosis. The general apoptotic mechanisms of statin is given in figure 1.10 (Dirks and Jones, 2006; Laufs and Liao, 2003; Matzno et al., 2005)

![Hypothetical Scheme of statin induced apoptosis](image)

**Figure 1.10.** Hypothetical Scheme of statin induced apoptosis (Dirks and Jones, 2006).

### 1.5 Spectroscopy

Spectroscopy is defined as the study of the interaction of electromagnetic wave with matter excluding chemical effects.
The energy \( E \) of the electromagnetic wave is given by the Bohr equation as:

\[
\Delta E = h \nu
\]

\( \nu \) is the frequency of the applied radiation and \( h \) is Planck’s constant (\( h = 6.6 \times 10^{-34} \) joule second).

\[
c = \lambda \nu
\]

where \( c \) is the speed of light in vacuum (\( 3.0 \times 10^8 \) ms\(^{-1} \)) and \( \lambda \) is the wavelength of light. These two equations can be used to identify a common spectroscopic unit called wavenumber, which is denoted by \( \nu \). Wavenumber is the number of waves in a length of one centimeter and expressed in terms of cm\(^{-1} \). It is given by the following relationship (Stuart, 1997):

\[
\bar{\nu} = \text{wavenumber} = 1/\lambda = \nu/c
\]

Thus, \( E = h \nu = h c \bar{\nu} \),

From these equations, it is clear that both wavenumber and frequency are directly proportional to energy. However, in practical applications of spectroscopy wavenumber is used because in the frequency, the numbers involved are often large.

As a result of electromagnetic radiation with matter, redirection of the radiation can be scattered (i.e. its direction of propagation changes), absorbed (i.e. its energy is transferred to the molecule) or emitted (energy is released by the molecule). The relative probability of the occurrence of each process is a property of the particular molecule encountered. When the energy of the light is absorbed, the molecule is said to be **excited** or in an excited state. An excited molecule can possess any one of a set of discrete amounts (quanta) of energy described by the laws of quantum mechanics. These amounts are called the **energy levels** of the molecule. A typical energy-level diagram describing these energy levels is presented in Figure 1.1. The major energy levels are determined by the possible spatial distributions of the electrons and are called electronic energy levels; on these are superimposed vibrational levels, which indicate the various
modes of vibration of the molecule (e.g., the stretching and bending of various covalent bonds). There are even smaller subdivisions called rotational levels, but they are of little importance in absorption spectroscopy. The lowest electronic level is called the ground state and all others are excited states (Freifelder, 1982).

\[
E_{\text{total}} = E_{\text{transition}} + E_{\text{rotation}} + E_{\text{vibration}} + E_{\text{electronic}} + E_{\text{electron spin orientation}} + E_{\text{nuclear spin orientation}}
\]

**Figure 1.11.** Typical energy-level diagrams showing the ground state and the first excited state. Vibrational levels are shown as thin horizontal lines. A possible electronic transition between the ground state and the fourth vibrational level of the first excited state is indicated by the long arrow. A vibrational transition within the ground state is indicated by the short arrow (Freifelder, 1982).

For most purposes, it is convenient to treat a molecule as if it possesses several distinct reservoirs of energy. The total energy is given by:
Each $E$ in the equation represents the appropriate energy as indicated by its subscript.

### 1.5.1 Infrared Spectroscopy

Infrared spectroscopy is the study of the interaction of infrared light with the electric dipole moment of the matter. The multiplicity of vibrations occurring simultaneously produces a highly complex absorption spectrum, which is the plot of absorption as a function of wavenumber ($\nu$) expressed in terms of cm$^{-1}$. The value of infrared spectral analysis comes from the fact that the modes of vibration of each group are very sensitive to the changes in chemical structure, conformation and environment. In addition, as each different material has a unique combination of atoms, no two compounds produce the exact same infrared spectrum. Therefore, an infrared spectrum can result in a positive identification of every different kind of material.

The term “infrared” covers the range of the electromagnetic spectrum between 0.78 and 1000 μm (Figure 1.15). The infrared spectrum can be divided into three regions: the far infrared (400-20 cm$^{-1}$), the mid infrared (4000-400 cm$^{-1}$) and the near infrared (14285-4000 cm$^{-1}$). Most infrared applications employ the mid-infrared region, but the near and far infrared regions can also provide information about certain materials.
Infrared spectroscopy has been used in a number of branches of science as a quantitative and qualitative tool (Diem, 1993, Garip et al., 2007, Gorgulu et al., 2007, Dogan et al., 2007, Bozkurt et al., 2007, Akkas et al., 2007). It is a nondestructive tool, which gives information about the structure of material.

An IR Spectrum of sample is obtained by scanning the intensity of IR radiation before and after passage of the IR beam. The IR Spectra of most materials consist of a large number of absorption bands. These bands originate from the interaction between discrete vibrational and rotational modes of the molecules which are excited by the absorption of IR radiation. Since the components of typical biological sample are present in a condensed phase (solids, liquids or solutions), only vibrational modes are observed. Consequently, IR spectra of biological specimens are only vibrational spectra (Colthup et al., 1990).

Different descriptive names are often given to vibrational modes. Vibrations can be subdivided into two classes, depending on whether the bond length or angle is changing:

![Electromagnetic Spectrum](Figure 1.12. The Electromagnetic spectrum)
1- Stretching (Symmetric and asymmetric): It produces a change of bond length. A stretch is a rhythmic movement along the line between the atoms so that the interatomic distance is either increasing or decreasing. A stretch can be symmetric or asymmetric

2- Bending (scissoring, rocking, wagging and twisting): results in a change in bond angle. Bending can occur in the plane of the molecule or out of plane; it can be scissoring, like blades of a pair of scissors, or rocking, where two atoms move in the same directions

Consequently, infrared spectra are generated by the characteristic motions of various functional groups (e.g. methyl, carbonyl, amide etc.). The sensitivity of these modes of vibration to any alteration in chemical structure, conformation, and environment presents the value of infrared spectroscopy. Figures 1.13, 1.14 and 1.15 demonstrate the main types of variations schematically.

For a vibration to give rise to absorption of infrared radiation, there are two criteria:

* A molecule should have a frequency of vibration similar to electromagnetic wave.

* Change of dipole moment should take place.
Upon interaction with infrared radiation, portions of the incident radiation are absorbed at particular wavelengths.
1.5.2 Fourier Transform Infrared Spectroscopy (FTIR)

Fourier transform infrared (FTIR) spectroscopy has found increasing favor in laboratories since early eighties. This method is based on the idea of the interference of radiation between two beams to yield an interferogram, which is a signal produced as a function of the change of pathlength between the two beams.

The most important feature of an interferogram is that every individual data point of this signal contains information over the entire infrared region. This process is carried out by an interferometer. It encodes the initial frequencies into a special form, which the detector can observe. For rapid-scanning interferometers, liquid nitrogen cooled mercury cadmium telluride (MCT) detectors are used. For slower scanning types of interferometer, pyroelectric detectors (e.g. a deuterated triglycine sulfate (DTGS) detector element) can be used. In essence, the detector is always observing all frequencies at the same time (Griffiths and De Haseth, 1986). The two domains of distance and frequency are interconvertible by the mathematical method of Fourier transformation. Therefore, Fourier transformation is simply a mathematical means of sorting out the individual frequencies for the final representation of an infrared spectrum.

The basic components of an FTIR spectrometer are shown schematically in Figure 1.16. The radiation emerging from the source is passed through an interferometer to the sample before reaching a detector. Upon amplification of the signal, in which, high frequency contributions have been eliminated by a filter, the data are converted to a digital form by an analog-to-digital converter and then transferred to the computer for Fourier transformation to be carried out.
Figure 1.16. Basic components of an FTIR spectrometer. (Stuart 2004)

![Diagram of FTIR components]

Figure 1.17. Schematic of a Michelson interferometer (Stuart 2004)

The most common interferometer used in FTIR spectrometry is a Michelson interferometer (Figure 1.17), which consists of two perpendicularly plane mirrors, one of which can travel in a direction perpendicular to the plane. A semi-reflecting film, a beamsplitter, bisects the planes of these two mirrors. The beamsplitter material has to be chosen according to the region to be examined. FTIR spectrometers use a Globar or Nernst source for the mid-infrared region. If the far-infrared region is to be examined, then a high-pressure mercury lamp can be used.
For the near-infrared, tungsten-halogen lamps are used as sources. The moving mirror is a crucial component of the interferometer. It has to be accurately aligned and must be capable of scanning two distances so that the path difference corresponds to a known value. A number of factors associated with the moving mirror need to be considered when evaluating an infrared spectrum. The interferogram is an analogue signal at the detector that has to be digitized in order that the Fourier-transformation into a conventional spectrum can be carried out (Stuart, 2004).

1.5.3 Attenuated Total Reflectance  FTIR Spectroscopy

FTIR spectra can be obtained from the transmission or reflection of IR radiation from the sample. In transmission measurements, the IR beam passes through the sample and it is applicable to solids, liquids, gases and polymers that allow transmission of source light whilst reflectance measurements are based on the reflection of IR radiation on the sample. They are classified as diffuse reflectance and Attenuated Total Reflectance (ATR) (Stuart, 2004).

ATR is especially useful for opaque solid samples regardless of thickness with a minimum time of preparation. Thin films, pastes, powders, suspensions, paper, coatings, and fibers can easily be analyzed with ATR technique. This technique utilizes the phenomenon of total internal reflection. A beam of radiation entering a crystal will undergo total internal reflection when the angle of incidence at the interface between the sample and crystal is greater than the critical angle, where the latter is a function of the refractive indices of the two surfaces. The beam penetrates a fraction of a wavelength beyond the reflecting surface and when a material that selectively absorbs radiation is in close contact with the reflecting surface, the beam loses energy at the where the material absorbs (Figure 1.18). The resultant attenuated radiation is measured and plotted as a function of wavelength.
by the spectrometer and gives rise to the absorption spectral characteristics of the sample (Stuart, 2004; Günzler and Gremlich, 2002).

The depth of penetration in ATR spectroscopy is a function of the wavelength (λ), the refractive index of the crystal (n₂) and the angle of incident radiation, (θ). The depth of penetration (d_p) for a non-absorbing medium is given by the following:

\[ d_p = \frac{\lambda}{n_2} \sqrt{2\pi \sin \theta \left( \frac{n_1}{n_2} \right)^2} \]

where n₁ is the refractive index of the sample.

The crystals used in ATR cells are made from materials that have low solubility in water and are of a very high refractive index. Such materials include zinc selenide (ZnSe), germanium (Ge) and thallium-iodide (KRS-5).
The properties of these commonly used materials for ATR crystals are summarized in table 1.6.

<table>
<thead>
<tr>
<th>Window material</th>
<th>Useful range (cm(^{-1}))</th>
<th>Refractive index</th>
<th>Depth of penetration (µm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>KRS-5</td>
<td>20 000-400</td>
<td>2.37</td>
<td>1.73</td>
</tr>
<tr>
<td>ZnSe</td>
<td>20 000-650</td>
<td>2.4</td>
<td>1.66</td>
</tr>
<tr>
<td>Si</td>
<td>8300-1500</td>
<td>2.37</td>
<td>1.73</td>
</tr>
<tr>
<td>Diamond</td>
<td>45000-2500</td>
<td>2.4</td>
<td>1.66</td>
</tr>
<tr>
<td>Ge</td>
<td>5000-550</td>
<td>4.0</td>
<td>0.65</td>
</tr>
</tbody>
</table>

Different designs of ATR cells allow both liquid and solid samples to be examined. It is also possible to set up a flow-through ATR cell by including an inlet and outlet in the apparatus. This allows for continuous flow of solutions through the cell and permits spectral changes to be monitored with time (Stuart, 2004).

1.5.4. The Advantages of FTIR and ATR-FTIR Spectroscopy

The reason why infrared spectroscopy is commonly used is that

- The spectra of almost any biological material can be obtained in a wide variety of environments.
It provides a precise measurement method, which requires no external calibration.

It is possible to examine all wavelengths arriving at the detector simultaneously, compared to being able to sample only one spectral element at a time by the detector (Diem, 1993).

This method is a rapid and sensitive technique, which is easy to perform to improve the signal-to-noise ratio (noise adds up as the square root of the number of scans, whereas signal adds linearly). The data processing is simple with the computer softwares. Moreover, system permits permanent data storage, manipulation of data and quantitative calculations (Rigas et al., 1990; Manoharan et al., 1993; Yono et al., 1996; Ci et al., 1999).

The instrumentation is inexpensive compared to the cost of X-Ray diffraction, NMR, ESR, and CD spectroscopic equipment.

Small sample quantities as low as few micrograms are sufficient to analyse and in vivo studies are possible (Mendelsohn and Mantsch, 1986).

It is a non-destructive technique (Melin et al., 2000, Severcan and Haris, 1999, Cakmak et al., 2003) and there is no light scattering or fluorescent effects.

The system can be applied to the analysis of any kind of material and that is not limited to the physical state of the sample. Samples may be solutions, viscous liquids, suspensions, inhomogeneous solids or powders (Colthup et al., 1990). Indeed, kinetic and time-resolved studies are possible (Mantsch et al., 1984; Mendelson and Mantsch, 1986; Haris and Severcan, 1999).

Frequency and bandwidth values can be determined routinely with uncertainties of better than ±0.05 cm\(^{-1}\).

Moreover, due to its somewhat different technology, it is used to examine functional groups that are not accessible with ultraviolet and visible light absorption spectrometers (Freiferder, 1982).
In addition to all advantages mentioned above, the other advantages of ATR-FTIR spectroscopy are the following: (Zhongsheng et al., 2007),

- A pure spectrum of any kind of sample is obtained easily in a short time as compared to transmission spectroscopy.
- ATR sampling is fast and easy because little or no sample preparation is required.
- Other techniques, such as infrared transmission, often require the sample to be heated, pressed or ground in order to collect the spectrum. These processing steps for transmission analysis take time and can cause structural changes to the sample. In addition, samples that must be diluted for transmission analysis are usually mixed with salts which may have spectral features of their own.
- Most samples can be run in their natural state (Graudolnik, 2002).
- The ATR-FTIR spectra have better signal-to-noise ratio and increased sensitivity.
- The ATR-FTIR spectra are similar to absorption spectra, but without significant spectral distortion.
- Compared to transmission experiments, it avoids the handling problems which are caused by the required short pathlength.

1.6 Aim of the Study

Statins are the most prescribed drugs in the world due to the higher efficacy. The mechanism of 3-hydroxyl-3-methylglutaryl-coenzyme-A reductase inhibitor-induced muscle side effects is not yet understood. A variety of statins have been shown to cause myopathy and rhabdomyolysis in animals and humans. A number of in vitro studies have investigated statin-induced myotoxicity; however there is currently no data about statin induced structural and functional changes of macromolecules in skeletal muscle and comparison of these changes in different type of muscles. To obtain a better understanding of the nature of the side effects of statins in muscle the present study examined
simvastatin-tissue interactions with regard to their ability to induced myotoxicity within the different rat skeletal muscle tissues, namely EDL, DIA and SOL. For this purpose FTIR and ATR-FTIR spectroscopy were used.

As mentioned before FTIR and ATR-FTIR spectroscopy are valuable techniques due to their high sensitivities in detecting changes, simultaneously in the functional groups belonging to tissue components. Both techniques are especially useful for the analysis of secondary structural characterization of proteins. These techniques are non-destructive, and highly selective because their ability to be a spectral fingerprint for molecular components.

The other aim of this study is to apply FTIR and ATR-FTIR spectroscopy as rapid and suitable methods to evaluate the effect of simvastatin on skeletal muscle tissues at molecular level and to compare these findings with biochemical and physiological data obtained in other studies.
CHARTER 2

MATERIALS AND METHODS

2.1 Reagents

Simvastatin (Zocor) were purchased from Merck, Sharp and Dohme (West Point, PA, USA) as tablets containing 40 mg in each. Potassium bromide (KBr), acetonitrile and isopropanol were obtained from Merck (Merck Company, Darmstadt, Germany), Butylated hydroxy toluene and cholesterol was purchased from Sigma (Sigma Chemical Company, Saint Louis, Missouri, USA). All chemicals were obtained from commercial sources at the highest grade of purity available.

2.2. Preparation of Experimental Animals

Twenty adult male Wistar rats (12-14 weeks) weighing 250-300 g which are obtained from Experimental Animal Center, Hacettepe University, Ankara, were selected randomly. The rats were fed with a standard diet with water ad libitum, and kept in conventional room with controlled light (12:12, dark:light), temperature (22±1 °C), relative humidity (40-50%) and ventilation (15 air changes per hour). They were allowed to adapt to their environment for one week prior to the experiments. All procedures were approved by the Ethics Committee of Hacettepe University.

The rats were separated into two groups as control (n=10) and simvastatin treated (n=10). The control group received only serum physiologic solution. Simvastatin in serum physiologic (50 mg/kg) were given to the treatment group daily through
gavage during 30 days (Figure 2.1). During the experiment, rats were weighed weekly. A definite amount of water and foods were given to the rats and remained food weighed and water measured by a graduated cylinder daily.

At the end of this period the rats were decapitated. The blood samples were taken for HPLC studies. EDL, SOL and DIA muscles were dissected separately and stored at −80 °C until FTIR spectroscopy study. In Figure 2.2 the surface of the tibia and the muscles of the left limb of rat, SOL muscle and tendon of EDL muscle can be seen. Figure 2.3 shows the caudal and dorsal surface of the rat diaphragm muscle. In this figure, the numbers between 4-10 represents the different parts of the rat diaphragm.

*Figure 2.1. Oral gavage method*
Figure 2.2. Rat lateral surface of the tibia and the muscles of the left limb; view of the dorsolateral surface, 8-10 m. extensor digitorium longus-long extensor muscle of digits, 13-m. soleus-soleus muscle (Popesco et al., 2002).
Figure 2.3. The dorsal and caudal surface of rat diaphragm. 4-10 diaphragm (Popesko *et al*., 2002; Olds, 1988).
2.3. High Pressure Liquid Chromatography (HPLC) Studies

**Total cholesterol analysis in serum:** Blood samples were collected in tubes for biochemical analysis, and centrifuged at 5000 x g at 4°C for 10 min to separate cells and serum. The serum samples were used for total cholesterol determination. 200 µL serum samples were extracted in 3 ml acetonitrile/isopropyl alcohol (70:30, v/v)-containing tubes and the mixture were vortexed for 30 s and centrifuged at 6000 x g for 10 min at 4 °C. Supernatants were transferred to autosampler vials of the HPLC instrument. In order to prevent the oxidation of cholesterol, BHT is added to both standard and serum cholesterol solutions. Acetonitrile-isopropyl alcohol (70:30 v/v) was used as mobile phase at a flow rate of 1 ml/ min. Supelcosil LC 18 DB column (250 x 4.6 mm, 5 µ m) was used as the HPLC column. Detection was performed by UV at 202 nm and 40 ° C column oven. Quantification was carried out by external standardization using *Class VP software*. The results were expressed µg/ml for serum samples (Yilmaz *et al.*, 2007).

2.4. Fourier Transform Infrared (FTIR) and Attenuated Total Reflectance Fourier Transform Infrared (ATR-FTIR) Spectroscopic Measurements

2.4.1 Sample Preparation for FT-IR and ATR-FTIR Studies

The EDL and SOL samples were dried in a LABCONCO freeze drier (Labconco FreeZone®, 6 liter Benchtop Freeze Dry System Model 77520) for overnight in order to remove water content. The dried samples were then ground in a liquid nitrogen-cooled colloid mill (Retsch MM200) to obtain tissue powder. The tissue powder was mixed with dried potassium bromide at the ratio of 0.5 mg sample to 150 mg KBr in a mortar. KBr is most commonly used alkali halide disk serving as a beam condensing system. It is completely transparent in the mid-infrared region (Stuart, 1997). The mixture was dried again in the freeze drier for 18 hours to remove all traces of remaining water.
The mixture then was compressed under a pressure of \( \sim 100 \text{kg/cm}^2 \) (1300psi) for 6 min to obtain a thin KBr disk. This sinters the mixture and produces a clear transparent disk (Stuart, 1997).

Diaphragm muscle has a very thin structure (Figure 2.3) and the distribution of muscle fiber types changes from costal to sternal part of the tissue. Due to the requirements of small samples and difficulties in the grinding of the diaphragm muscle tissues for FTIR studies, these tissues were studied with ATR-FTIR spectroscopy. For ATR-FTIR studies, the samples in size of 0.5 cm x 0.5 cm x 0.1 cm were cut from costal part of rat diaphragm muscles.

2.4.2 FTIR and ATR-FTIR spectroscopy

Infrared spectra of EDL and SOL samples were obtained using Perkin-Elmer Spectrum 100 FTIR spectrometer (Perkin-Elmer Inc., Norwalk, CT, USA) equipped with a MIR TGS detector. Water and carbondioxide molecules in the air affect the IR spectrum. Moreover, although KBr is always infrared spectroscopic grade, it may give some small absorption bands interfering with sample spectra. To overcome these problems the spectrum of air and KBr transparent disk was recorded together as background and substracted automatically by using appropriate software (Spectrum1000 software).

The spectra of EDL and SOL samples were recorded in the 4000–400 cm\(^{-1}\) region at room temperature. A total of 50 scans were taken for each interferogram at 4 cm\(^{-1}\) resolution.

The infrared spectra of diaphragm muscle samples were collected in the one-bounce ATR mode in a Spectrum 100 FTIR spectrometer (Perkin-Elmer Inc., Norwalk, CT, USA) equipped with a Universal ATR accessory. The small diaphragm muscle samples were placed on a Diamond/ZnSe crystal plate (Figure 2.4) (PerkinElmer) and compressed (150 Gauge) with a sponge to
obtain good surface contact. The tissues were scanned from 4000 to 650 cm\(^{-1}\) for 50 scans with a resolution of 4 cm\(^{-1}\) at room temperature. Water was used as a reference. Since the diaphragm tissue contains water, this water was subtracted automatically from the tissue spectra by using Spectrum 100 software.

![Figure 2.4. The sample position on ATR-FTIR Spectroscopy](image)

Each sample was scanned under the same conditions with three different pellets, all of which gave identical spectra. The average spectra of these three replicates were used in detailed data analysis and statistical analysis.
Collections of spectra and data manipulations were carried out using Spectrum 100 software (Perkin-Elmer). The band positions were measured using the frequency corresponding to the center of weight. Using the same software, the spectra were first smoothed with nineteen-point Savitsky-Golay smooth function to remove the noise. After the averages of three replicates of the same samples were taken, the spectra were baseline corrected. The spectra were normalized with respect to specific bands for visual demonstration. The purpose of the normalization is to remove differences in peak heights between the spectra acquired under different conditions. It allows a point-to-point comparison to be made (Smith, 1999). The ratios of the intensities and shifting of the frequencies were examined before the normalization process. Band areas were calculated from smoothed and baseline corrected spectra using Spectrum 100 software. The bandwidth values of specific bands were calculated as the width at 0.75x height of the signal in terms of cm⁻¹.

2.4.3. Cluster Analysis

In order to the spectral differentiation of control and simvastatin-treatment groups in each type of skeletal muscle and control groups of EDL, SOL and DIA muscles, cluster analysis was applied by using OPUS 5.5 software (Bruker Optics, GmbH). For cluster analysis, second derivative of each spectrum was taken in 3800-850 cm⁻¹ region and subsequently vector normalization was applied over the investigated frequency range. As input data for this analysis, spectral distances were calculated between pairs of spectra as Pearson’s correlation coefficients. Cluster analysis for the separation of control and treatment groups were based on the Euclidean distances. Ward’s algorithm was used to construct dendrograms.
2.5 Statistical Test

The results were expressed as ‘mean ± standard deviation (SD)’. Control and simvastatin treated data were analyzed statistically using non-parametric Mann–Whitney U test. A ‘p’ value less than or equal to 0.05 was considered as statistically significant. The degree of significance was denoted as less than or equal to p<0.05*, p<0.01**, p<0.001***.
CHAPTER 3

RESULTS

This current study was specifically conducted to reveal the effects of high dose of simvastatin treatment on the macromolecular compositions, structure and function of different rat skeletal muscle tissue types: EDL, SOL and DIA by using ATR-FTIR and FTIR spectroscopy.

3.1 Body Weights, Food, Drug Intake and Serum Cholesterol Levels of Rats

Animals were weighed both before treatment and decapitation. A definite food and water was given to animals everyday and remaining food and water amount were measured. The body weights, food and water consumption values of control and treated groups were given in Table 3.1. Simvastatin treatments caused significant decrease in the body weight (p<0.05), food (p<0.01) and water intake (p<0.001).

After decapitation, serum cholesterol levels were measured by HPLC. The results were given in Figure 3.1. As seen from the Figure, the total cholesterol values in rat serum samples decreased significantly from 172.06±11.83 µg/ml to 146.63±11.22 µg/ml (p<0.01) as a result of the simvastatin treatment as expected.
Table 3.1. Food intake, water intake and body weight in rats treated with simvastatin. The values are the mean ± S.D. for each group. Comparisons were done by Mann–Whitney U-test. The degree of significance was denoted as: $p < 0.05^*$, $p < 0.01^{**}$, $p < 0.001^{***}$. Downward arrow indicates a decrease and upward arrow indicates an increase with respect to the control.

<table>
<thead>
<tr>
<th>Animal Group</th>
<th>Control</th>
<th>Simvastatin Treated Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial body weight (g)</td>
<td>262±12</td>
<td>277±11</td>
</tr>
<tr>
<td>Final body weight (g)</td>
<td>267±15↑</td>
<td>260±13↓*</td>
</tr>
<tr>
<td>Food intake (g/rat)</td>
<td>19.11±2.65</td>
<td>15.50±3.05↓**</td>
</tr>
<tr>
<td>Water intake (ml/one rat)</td>
<td>29.75±4.20</td>
<td>21.18±3.27↓***</td>
</tr>
</tbody>
</table>

Figure 3.1. Serum total cholesterol values in control and simvastatin treated animals
3.2. Infrared Spectroscopy Studies

3.2.1. General FTIR and ATR-FTIR Spectrum and Band Assignment of Skeletal Muscle Tissue

The present FT-IR study primarily based on the investigation of the structural and compositional variations in macromolecules and lipid fluidity in between simvastatin treated and untreated different rat skeletal muscles, namely, EDL, SOL and DIA. EDL is largely composed of type II fibers whereas SOL muscle largely composed of type I fibers. On the other hand, rat DIA consists of a substantial proportion of type I fibers (Kilarski and Sjostrom, 1990; Ariano et al., 1973; Delp et al., 1996).

Since the positions and intensities of many of the infrared absorption bands can be correlated with the presence of specific groups of atoms in the system studied (Steele, 1971), it is possible to assign specific wavelength molecular absorption bands to specific vibrational modes of particular functional groups. In the present study, the same approach was applied.

Figure 3.2 A and 3.2 B demonstrate the representative infrared spectra of control EDL, SOL and DIA muscles in the region of 3850-850 cm\(^{-1}\). The main bands are labeled in the figures and detailed band assignments are based upon this work and other studies cited in literature are given in Table 3.2 (Rigas et al., 1990; Wong et al., 1991; Takahashi et al., 1991; Wang et al., 1997; Jamin et al., 1998; Melin et al., 2000; Jackson et al., 1998; Lyman et al., 1999; Chiriboga et al., 2000; Çakmak et al., 2003, Banyay et al., 2003; Toyran et al., 2006, Cakmak et al., 2006).

As seen from the figures, there are marked differences in the intensity/area and frequency values of the control groups of EDL, SOL and DIA muscles.
Figure 3.2. A The representative infrared spectra of control groups of EDL and SOL muscles in the 3850-850 cm\(^{-1}\) region. (The spectra were normalized with respect to the Amide A band, around 3350 cm\(^{-1}\))
Figure 3.2. B The representative infrared spectrum of control groups of Diaphragm muscle in the 3850-850 cm\(^{-1}\) region. (The spectra were normalized with respect to the Amide A band, around 3350 cm\(^{-1}\))
Table 3.2. General band assignment of rat skeletal muscle

<table>
<thead>
<tr>
<th>Peak no.</th>
<th>Wavenumber (cm⁻¹)</th>
<th>Definition of the spectral assignment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>3400</td>
<td>O-H stretching (Amide A), hydrogen-bonded intermolecular OH groups of proteins and glycogen</td>
</tr>
<tr>
<td>2</td>
<td>3330-3290</td>
<td>Mainly N-H stretching (Amide A) of proteins with the little contribution from O-H stretching of polysaccharides and intermolecular H bonding</td>
</tr>
<tr>
<td>3</td>
<td>3062</td>
<td>C-N and N-H stretching (Amide B) of protein</td>
</tr>
<tr>
<td>4</td>
<td>3014</td>
<td>Olefinic=CH stretching vibration: unsaturated lipids, cholesterol esters</td>
</tr>
<tr>
<td>5</td>
<td>2962</td>
<td>CH₃ asymmetric stretching: mainly lipids, with the little contribution from proteins, carbohydrates, nucleic acids</td>
</tr>
<tr>
<td>6</td>
<td>2929</td>
<td>CH₂ asymmetric stretching: mainly lipids, with the little contribution from proteins, carbohydrates, nucleic acids</td>
</tr>
<tr>
<td>7</td>
<td>2874</td>
<td>CH₂ symmetric stretching: mainly proteins, with the little contribution from lipids, carbohydrates, nucleic acids</td>
</tr>
<tr>
<td>8</td>
<td>2855</td>
<td>CH₃ symmetric stretching: mainly lipids, with the little contribution from proteins, carbohydrates, nucleic acids</td>
</tr>
<tr>
<td>9</td>
<td>1739–1744</td>
<td>Ester C=O stretch: triglycerides, cholesterol esters</td>
</tr>
<tr>
<td>10</td>
<td>1656</td>
<td>Amide I (protein C=O stretching)</td>
</tr>
<tr>
<td>11</td>
<td>1540</td>
<td>Amide II (protein N-H bend, C-N stretch)</td>
</tr>
<tr>
<td>12</td>
<td>1452</td>
<td>CH₂ bending: mainly lipids, with the little contribution from proteins</td>
</tr>
<tr>
<td>13</td>
<td>1392</td>
<td>COO⁻ symmetric stretching: fatty acids</td>
</tr>
<tr>
<td>14</td>
<td>1343</td>
<td>Amide III vibrations of collagen</td>
</tr>
<tr>
<td>15</td>
<td>1261</td>
<td>PO₄²⁻ asymmetric stretching, non-hydrogen-bonded: mainly nucleic acids with the little contribution from phospholipids</td>
</tr>
<tr>
<td>16</td>
<td>1236</td>
<td>PO₄²⁻ asymmetric stretching, fully hydrogen-bonded: mainly nucleic acids with the little contribution from phospholipids</td>
</tr>
<tr>
<td>17</td>
<td>1170</td>
<td>CO–O–C asymmetric stretching: ester bonds in cholesterol esters and phospholipids</td>
</tr>
<tr>
<td>18</td>
<td>1080</td>
<td>PO₄²⁻ symmetric stretching: nucleic acids and phospholipids C-O stretch: glycogen, polysaccharides, glycolipids</td>
</tr>
<tr>
<td>19</td>
<td>1040</td>
<td>C-O stretching: polysaccharides (glycogen)</td>
</tr>
<tr>
<td>20</td>
<td>976</td>
<td>C-N¹-C stretch: nucleic acids, ribose-phosphate main chain vibrations of RNA</td>
</tr>
<tr>
<td>21</td>
<td>929</td>
<td>Z type of DNA</td>
</tr>
<tr>
<td>22</td>
<td>876</td>
<td>Vibrations in N-type sugars in nucleic acid backbone</td>
</tr>
</tbody>
</table>
3.2.2 Comparison of Spectra of Skeletal Muscle Fiber Types

3.2.2.1 Comparison of Control and Simvastatin EDL Skeletal Muscle Fiber

Although the FTIR spectral data were collected over the frequency range of 4000-400 cm\(^{-1}\), in order to display the details of spectral changes, the analysis was performed in three distinct frequency ranges: 3750-3025 cm\(^{-1}\), 3025-2800 cm\(^{-1}\) and 1850-850 cm\(^{-1}\). It is seen that the control spectra are almost overlapped with each other. The simvastatin treated spectra are also almost overlapped with each other. For this reason, only one control and simvastatin treated spectra are chosen as a representative spectrum for each group in the following discussion.

Figure 3.3 and Figure 3.4 show the representative infrared spectra of control and simvastatin treated EDL muscle in 3750-3025 cm\(^{-1}\) and 3025-2800 cm\(^{-1}\) regions, respectively. As it could be seen from these figures control and simvastatin treated spectra noticeably differ in peak positions, peak heights and bandwidths in these regions.
Figure 3.3. The representative infrared spectra of control and simvastatin treated EDL muscles in the 3750-3025 cm\(^{-1}\) region (The spectra were normalized with respect to the CH\(_2\) asymmetric stretching mode at 2925 cm\(^{-1}\)).

Figure 3.4. The representative infrared spectra of control and simvastatin treated EDL muscles in the 3025-2800 cm\(^{-1}\) region (The spectra were normalized with respect to the CH\(_2\) asymmetric stretching mode at 2925 cm\(^{-1}\)).
Figure 3.5 demonstrates the representative infrared spectra of control and simvastatin treated EDL muscle in 1850-850 cm\(^{-1}\) region. As it could be seen from the figure, the control and simvastatin treated spectra represent remarkable differences in bandwidth, intensity and frequency values in this region. These differences between the control and simvastatin treated spectra will be discussed in detail.
Figure 3.5. The representative infrared spectra of control and simvastatin treated EDL muscles in the 1850-850 cm\(^{-1}\) region (The spectra were normalized with respect to the Amide I at 1645 cm\(^{-1}\))
Concerning these spectral differences, the control and simvastatin treated EDL muscles were differentiated using cluster analysis with a high accuracy (success rate 7/10 for treated, 8/10 control for tissues). The result is demonstrated in Figure 3.6.
Figure 3.6. Hierarchical clustering of control and simvastatin treated EDL muscles using second derivative spectra (spectral range: 3850-850 cm⁻¹). The sample labeled with * was not clearly differentiated, and not used in statistical analysis.
3.2.2.2 Comparison of Control and Simvastatin Treated DIA Skeletal Muscle

Figure 3.7, Figure 3.8 and Figure 3.9 show the infrared spectra of control and simvastatin treated DIA muscle in 3750-3025 cm\(^{-1}\), 3025-2800 cm\(^{-1}\) and 1800-850 cm\(^{-1}\) regions, respectively. As it could be seen from these figures, the control and simvastatin treated spectra considerably differ in peak positions, peak heights and widths in all regions. These differences between the control and simvastatin treated samples will be discussed later more specifically. The differences in variables are seemed to be similar to main spectral bands observed in part 3.2.2.1, the spectra of EDL muscle.

Cluster analysis was performed based on second derivative FTIR spectra to differentiate between the control and simvastatin treated DIA muscles. As seen from the Figure 3.10, the control and simvastatin treated samples are discriminated with a high accuracy (success rate 8/10 for treated, 9/10 for control tissues).
Figure 3.7. The representative infrared spectra of control and simvastatin treated EDL muscles in the 3750-3025 cm$^{-1}$ region (The spectra were normalized with respect to the CH$_2$ asymmetric stretching mode at 2925 cm$^{-1}$)

Figure 3.8. The representative infrared spectra of control and simvastatin treated EDL muscles in the 3025-2800 cm$^{-1}$ region (The spectra were normalized with respect to the CH$_2$ asymmetric stretching mode at 2925 cm$^{-1}$)
Figure 3.9. The representative infrared spectra of control and simvastatin treated DIA muscles in the 1800-850 cm\(^{-1}\) region (The spectra were normalized with respect to the Amide I at 1645 cm\(^{-1}\))
Figure 3.10. Hierarchical clustering of control and simvastatin treated DIA muscles using second derivative spectra (spectral range: 3850-850 cm\(^{-1}\)). The sample labeled with * was not clearly differentiated, and not used in statistical analysis.
3.2.2.3 Comparison of Control and Simvastatin Treated SOL Skeletal Muscle

The infrared spectra of control and simvastatin treated SOL muscle in 3750-3025 cm\(^{-1}\), 3025-2800 cm\(^{-1}\) and 1850-850 cm\(^{-1}\) regions are shown in Figures 3.11, 3.12 and 3.13 respectively. There are variations in peak positions, peak heights and bandwidths in the three regions which are seen in these figures. These differences between the control and simvastatin treated spectra will be discussed later more specifically. The differences in variables are seemed to be similar to the other skeletal muscles observed in part 3.2.2.1 and part 3.2.2.2, the spectra of EDL and DIA muscles, respectively.

To obviously view these spectral differences, cluster analysis was performed based on the second derivative FTIR spectra to differentiate between the control and simvastatin treated SOL muscles. As seen from the Figure 3.14, the control and treated groups can be differentiated with a high accuracy (success rate 9/10 for treated, 9/10 for control tissues).
Figure 3.11. The representative infrared spectra of control and simvastatin treated SOL muscles in the 3750-3025 cm$^{-1}$ region (The spectra were normalized with respect to the CH$_2$ asymmetric stretching mode at 2925 cm$^{-1}$)

Figure 3.12. The representative infrared spectra of control and simvastatin treated SOL muscles in the 3025-2800 cm$^{-1}$ region (The spectra were normalized with respect to the CH$_2$ asymmetric stretching mode at 2925 cm$^{-1}$)
Figure 3.13. The representative infrared spectra of control and simvastatin treated SOL muscles in the 1850-850 cm\(^{-1}\) region (The spectra were normalized with respect to the Amide I at 1645 cm\(^{-1}\))
Figure 3.14. Hierarchical clustering of control and simvastatin treated SOL muscles using second derivative spectra (spectral range: 3850-850 cm\(^{-1}\)). The sample labeled with * was not clearly differentiated, and not used in statistical analysis.
3.2.3 Numerical Comparisons of the Bands of Control and Simvastatin Treated Spectra of EDL, DIA and SOL Muscles

In order to clarify the possible spectral differences that could be observed between the individuals of even the same group, the means and the standard deviations of the band areas and direction of the shifts with respect to the control were taken into consideration for the control and simvastatin treated groups of EDL, DIA and SOL muscles. Mann-Whitney U-test was applied and the significance values were calculated.

3.2.3.1 Comparisons of Control and Simvastatin Treated Spectra of EDL, DIA and SOL Muscles in the 3750-3025 cm\(^{-1}\) Region

Figure 3.3, 3.7 and 3.11 demonstrate the normalized infrared spectra of the control and simvastatin treated EDL, DIA and SOL muscles in the 3750-3025 cm\(^{-1}\) region, respectively. The band located between 3370-3330 cm\(^{-1}\) (Amide A) contains strong absorptions arising from the N-H and the O-H stretching modes of proteins and polysaccharides intermolecular H bonding. This band was located at 3330 cm\(^{-1}\) and 3357 cm\(^{-1}\) in the spectrum of EDL and SOL, respectively. On the other hand, amide A appeared as two separated bands (3420 cm\(^{-1}\), 3290 cm\(^{-1}\)) in the spectrum of diaphragm. As it can be seen from the figures and Table 3.3, simvastatin–treatment lowered the area value of this band in the three muscle types, but most dramatically for EDL muscle (p<0.05*). A more clear representation of the changes in the areas of all types of the muscles is shown in Figure 3.15. The relative weak band located at 3072 cm\(^{-1}\) (Amide B) arises from C-N and N-H stretching of protein. A great decrease was also observed in the area of this band for EDL muscle (p<0.05*). As it can be seen from Table 3.4, the frequency of Amide A band shifted to a higher values in all muscles but this shifting was and more profound and significant for EDL muscle. The frequency of Amide B also shifted to higher values in simvastatin treated DIA and SOL muscles from 3075.76± 0.78 to
3077.88± 1.15 (p<0.01**) and from 3065.72± 0.98 to 3067.31± 1.26 cm\(^{-1}\) (p<0.05*) respectively. However, in simvastatin treated EDL muscle the frequency of this band shifted to more profoundly the higher values from 3062.60±1.34 to 3071.82± 2.08 cm\(^{-1}\) (p<0.01**).

**Figure 3.15.** Comparison of Amide A area for control and simvastatin treated groups of EDL, DIA and SOL muscles. * shows significance of p<0.05.
Table 3.3. The changes in the band area values of the control and simvastatin treated EDL, DIA and SOL spectra in 3750-3025 cm\(^{-1}\) region. The values are the mean ± Standard Deviation for each sample. The degree of significance was denoted as \(p<0.05\).

<table>
<thead>
<tr>
<th>Band No</th>
<th>Control EDL (n=8)</th>
<th>Sim.Tr. EDL (n=7)</th>
<th>Control DIA (n=9)</th>
<th>Sim.Tr. DIA (n=8)</th>
<th>Control SOL (n=9)</th>
<th>Sim.Tr. SOL (n=9)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td>9.50±0.97</td>
<td></td>
<td>8.77±1.15</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>45.71±3.38</td>
<td>39.10±2.63 *\†</td>
<td>15.48±4.36</td>
<td>14.48±1.85</td>
<td>31.11±5.05</td>
<td>30.61±5.74</td>
</tr>
<tr>
<td>3</td>
<td>4.87±0.81</td>
<td>3.97±0.47 * \†</td>
<td>4.96±0.53</td>
<td>4.61±0.45</td>
<td>2.64±0.51</td>
<td>2.47±0.79</td>
</tr>
</tbody>
</table>

Table 3.4. The changes in the band frequency values of the control and simvastatin treated EDL, DIA and SOL spectra in 3750-3025 cm\(^{-1}\) region. The values are the mean ± Standard Deviation for each sample. The degree of significance was denoted as \(p<0.05\), \(p<0.01\).

<table>
<thead>
<tr>
<th>Band No</th>
<th>Control EDL (n=8)</th>
<th>Sim.Tr.EDL (n=7)</th>
<th>Control DIA (n=9)</th>
<th>Sim.Tr. DIA (n=8)</th>
<th>Control SOL (n=9)</th>
<th>Sim.Tr. SOL (n=9)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
<td>3429.55±3.14</td>
<td>3431.58±5.56</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>3336.33 ± 8.43</td>
<td>3346.26± 6.77*\†</td>
<td>3290.65±1.56</td>
<td>3290.81±0.89\†</td>
<td>3356.76±14.38</td>
<td>3357.76±10.73\†</td>
</tr>
<tr>
<td>3</td>
<td>3062.60±1.34</td>
<td>3071.82±2.08*\†</td>
<td>3075.76±0.78</td>
<td>3077.88±1.15*\†</td>
<td>3065.72±0.98</td>
<td>3067.31±1.26*\†</td>
</tr>
</tbody>
</table>
3.2.3.2 Comparisons of Control and Simvastatin Treated Spectra of EDL, DIA and SOL Muscles in the 3025-2800 cm\(^{-1}\) Region

Figure 3.4, 3.8 and 3.12 show the normalized infrared spectra of control and simvastatin treated EDL, DIA and SOL muscles in 3025-2800 cm\(^{-1}\) region, respectively. The band located at 3010 cm\(^{-1}\), which is due to the CH stretching mode of the HC=CH groups, can be used as a measure of unsaturation in the phospholipid acyl chains (Takahashi et al., 1991; Melin et al., 2000; Liu et al., 2002; Severcan et al., 2005). There was a decrease in the area of this band in all muscle types, and this decrease was more dramatic in EDL muscle (p<0.01**) (Table 3.5). A more clear representation of the changes in the areas of all types of the muscles is shown in Figure 3.16. The frequency of this band shifted significantly to a higher value in simvastatin treated EDL muscle from 3010.49 ± 0.69 to 3011.56± 0.94 cm\(^{-1}\) (p<0.05*) (Table 3.6).
Figure 3.16. Comparison of =CH olefinic band area for control and simvastatin treated groups of EDL, DIA and SOL muscles. ** and *** show significances of p<0.01 and p<0.001 respectively.

The CH₃ asymmetric (2959 cm⁻¹), the CH₂ asymmetric (2927 cm⁻¹), and the CH₂ symmetric (2857 cm⁻¹) stretching bands originate mainly from lipids, whereas the the CH₃ (2876 cm⁻¹) symmetric stretching band originate mainly from proteins (Table 3.2) (Mantsch, 1984; Severcan et al. 1997; Severcan et al., 2000; Severcan et al., 2003, Cakmak et al., 2006).
**Table 3.5.** The changes in the band area values of the control and simvastatin treated EDL, DIA and SOL spectra in 3025-2800 cm⁻¹ region. The values are the mean ± Standard Deviation for each sample. The degree of significance was denoted as p<0.05*, p<0.01**, p<0.001***.

<table>
<thead>
<tr>
<th>Band No</th>
<th>Control EDL (n=8)</th>
<th>Sim. Tr. EDL (n=7)</th>
<th>Control DIA (n=9)</th>
<th>Sim. Tr. DIA (n=8)</th>
<th>Control SOL (n=9)</th>
<th>Sim. Tr. SOL (n=9)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>1.26±0.20</td>
<td>0.72±0.14**↓</td>
<td>0.69±0.08</td>
<td>0.62±0.02***↓</td>
<td>0.93±0.16</td>
<td>0.89±0.11↓</td>
</tr>
<tr>
<td>5</td>
<td>2.86±0.47</td>
<td>2.39±0.25*↓</td>
<td>2.19±0.18</td>
<td>2.13±0.07↓</td>
<td>2.21±0.32</td>
<td>1.92±0.31*↓</td>
</tr>
<tr>
<td>6</td>
<td>3.44±0.22</td>
<td>3.08±0.28*↓</td>
<td>2.90±0.25</td>
<td>2.71±0.10↓</td>
<td>4.15±0.67</td>
<td>3.98±0.54↓</td>
</tr>
<tr>
<td>7</td>
<td>0.79±0.13</td>
<td>0.58±0.11*↓</td>
<td>0.53±0.05</td>
<td>0.49±0.19*↓</td>
<td>0.49±0.06</td>
<td>0.42±0.03↓</td>
</tr>
<tr>
<td>8</td>
<td>0.88±0.12</td>
<td>0.73±0.09*↓</td>
<td>0.61±0.06</td>
<td>0.53±0.02*↓</td>
<td>1.07±0.29</td>
<td>0.96±0.18↓</td>
</tr>
</tbody>
</table>
Table 3.6. The changes in the band area values of the control and simvastatin treated EDL, DIA and SOL spectra in 3025-2800 cm\(^{-1}\) region. The values are the mean ± Standart Deviation for each sample. The degree of significance was denoted as \(p<0.05\*\).

<table>
<thead>
<tr>
<th>Band No</th>
<th>Control EDL (n=8)</th>
<th>Sim.Tr.EDL (n=7)</th>
<th>Control DIA (n=9)</th>
<th>Sim.Tr.DIA (n=8)</th>
<th>Control SOL (n=9)</th>
<th>Sim.Tr.SOL (n=9)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>3010.49± 0.69</td>
<td>3011.56± 0.54*↑</td>
<td>3011.32± 0.79</td>
<td>3011.98± 0.41↑</td>
<td>3010.56± 1.34</td>
<td>3010.59± 0.94↑</td>
</tr>
<tr>
<td>5</td>
<td>2961.09± 0.57</td>
<td>2960.56± 0.84↓</td>
<td>2958.31± 0.69</td>
<td>2958.26± 1.14↓</td>
<td>2958.12± 0.73</td>
<td>2957.89± 1.33↓</td>
</tr>
<tr>
<td>6</td>
<td>2927.60± 0.27</td>
<td>2926.82± 0.54*↓</td>
<td>2927.71± 1.27</td>
<td>2927.39± 0.6↓</td>
<td>2925.99± 0.28</td>
<td>2925.89± 0.20↓</td>
</tr>
<tr>
<td>7</td>
<td>2873.81± 0.48</td>
<td>2873.35± 0.63↓</td>
<td>2873.78± 0.73</td>
<td>2873.63± 0.60↓</td>
<td>2873.55± 0.37</td>
<td>2873.4± 1.76↓</td>
</tr>
<tr>
<td>8</td>
<td>2854.68± 0.53</td>
<td>2854.45± 0.28↓</td>
<td>2854.72± 0.62</td>
<td>2854.53± 0.20↓</td>
<td>2854.67± 0.33</td>
<td>2854.49± 0.83↓</td>
</tr>
</tbody>
</table>
In all simvastatin treated groups for different muscle types there was a reduction in the areas of the CH\(_3\) asymmetric and symmetric stretching vibrations but more profoundly for simvastatin treated EDL muscle (p<0.05*) (Table 3.5). The frequency of these bands in simvastatin treated groups shifted to lower frequency values for all muscle types. However these changes were insignificant (Table 3.6).

The CH\(_2\) stretching vibrations depend on the degree of conformational disorder; hence they can be used to monitor the average trans/gauche isomerization (order/disorder state of lipids) in the system (Mantsch et al., 1984; Severcan, 1997; Bizeau et al., 2000). An increase in the frequency of the CH\(_2\) stretching means an increase in the number of gauche conformers in the fatty acyl chains (Rana et al., 1990; Schultz et al., 1991; Melin et al., 2000; Cakmak et al., 2003; Cakmak et al., 2006). As seen from Figures 3.4, 3.8 and 3.12, the areas of the CH\(_2\) asymmetric and symmetric stretching vibrations located at 2927 cm\(^{-1}\) and 2854 cm\(^{-1}\) respectively, decreased in all three types of muscles. This decrease was more profound for EDL muscle in both bands (p<0.05*). The frequency of the CH\(_2\) asymmetric stretching band shifted to a lower frequency value in simvastatin treated EDL muscle from 2927.60 ± 0.27 to 2926.82 ± 0.54 cm\(^{-1}\), with a significance value of p<0.05*. In simvastatin treated DIA and SOL muscle the frequency of this band shifted slightly to a lower frequency and the changes were insignificant. A more clear representation of the variations in the band frequencies of all types of the muscles is shown in Figure 3.17. The frequency of the CH\(_2\) symmetric stretching band shifted to a lower frequency value in all muscle types insignificantly.

The bandwidth of the CH\(_2\) symmetric modes gives information about the membrane fluidity. As it can be seen from Table 3.7, there was a significant increase in the bandwidth value of this band in all muscle types but more profoundly for EDL muscle (p<0.01**).
The amount of proteins and lipids in the membranes is an important factor affecting the membrane structure and dynamics (Szalontai et al., 2000). From the FTIR spectrum, a precise lipid-to-protein ratio can be derived by taking the ratio of the sum of the areas of the lipid bands namely CH$_2$ asymmetric and symmetric stretching bands to the area of the CH$_3$ symmetric stretching band (protein). As it is seen from Table 3.8, an increase in this ratio was observed in the treatment groups which is more profound for EDL muscle (p< 0.05*).
Table 3.7. The changes in the bandwidth of the control and simvastatin treated EDL, DIA and SOL spectra. The values are the mean ± Standard Deviation for each sample. The degree of significance was denoted as $p<0.05$, $p<0.01$. The degree of significance was denoted as $p<0.05$.

<table>
<thead>
<tr>
<th>Band Name</th>
<th>Control EDL (n=8)</th>
<th>Sim. Tr. EDL (n=7)</th>
<th>Control DIA (n=9)</th>
<th>Sim. Tr. DIA (n=8)</th>
<th>Control SOL (n=9)</th>
<th>Sim. Tr. SOL (n=9)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CH$_2$ symmetric</td>
<td>11.34±0.17</td>
<td>11.59±0.29**↑</td>
<td>10.30±0.1</td>
<td>10.44±0.26*↑</td>
<td>11.78±0.06</td>
<td>11.89±0.10*↑</td>
</tr>
</tbody>
</table>

Table 3.8 The changes in the lipid-to-protein ratio of the bands for control and simvastatin treated EDL, DIA and SOL muscles. The values are the mean ± Standard Deviation for each sample. The degree of significance was denoted as $p<0.05$.

<table>
<thead>
<tr>
<th>Ratio of Peak Areas (lipid to protein)</th>
<th>Control EDL (n=8)</th>
<th>Sim. Tr. EDL (n=7)</th>
<th>Control DIA (n=9)</th>
<th>Sim. Tr. DIA (n=8)</th>
<th>Control SOL (n=9)</th>
<th>Sim. Tr. SOL (n=9)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CH$_2$ Asym. strech. + CH$_2$ Sym. strech./ CH$_3$ Sym. Strech.</td>
<td>5.57 ± 0.07</td>
<td>6.80 ± 0.17*↑</td>
<td>6.55±0.20</td>
<td>6.69±0.29↑</td>
<td>10.61±0.89</td>
<td>11.65±1.80↑</td>
</tr>
</tbody>
</table>
3.2.3.3 Comparison of Control and Simvastatin Treated Spectra of EDL, DIA and SOL Muscles in the 1850-850 cm\(^{-1}\) Region

The 1850-800 cm\(^{-1}\) frequency range is called as fingerprint region, includes several bands that originate from the interfacial and head-group modes of the membrane lipids, protein and nucleic acid vibrational modes (Mendelsohn and Mantsch, 1986). Figure 3.5, 3.9 and 3.13 demonstrate the normalized infrared spectra of control and simvastatin treated EDL, DIA and SOL muscles in 1850-850 cm\(^{-1}\) region, respectively.

The band centered at 1742 cm\(^{-1}\) is mainly assigned to the >C=O ester stretching vibration in phospholipids (Melin \textit{et al.}, 2000; Cakmak \textit{et al.}, 2003; Severcan \textit{et al.}, 2003). As illustrated in the Figure 3.5, 3.9 and 3.13 and Table 3.9, the area of this band decreased in the all simvastatin treated skeletal muscle types. However, this decrease was significant for EDL muscle (p<0.05*). A more clear representation of the changes in the areas of all types of muscles is shown in Figure 3.18. In addition, the wavenumber values of this vibration shifted to higher values in three muscle types but more dramatically for EDL muscle (p < 0.01**) (Table 3.10).
Table 3.9. The changes in the band area values of the control and simvastatin treated EDL, DIA and SOL spectra in 1850-850 cm$^{-1}$ region. The values are the mean $\pm$ Standart Deviation for each sample. The degree of significance was denoted as $p<0.05^*$, $p<0.01^{**}$, $p<0.001^{***}$.

<table>
<thead>
<tr>
<th>Band No</th>
<th>Control EDL (n=8)</th>
<th>Sim.Tr.EDL (n=7)</th>
<th>Control DIA (n=9)</th>
<th>Sim.Tr.DIA (n=8)</th>
<th>Control SOL (n=9)</th>
<th>Sim.Tr. SOL (n=9)</th>
</tr>
</thead>
<tbody>
<tr>
<td>9</td>
<td>3.08±0.35</td>
<td>2.57±0.27$^*\downarrow$</td>
<td>0.32±0.07</td>
<td>0.31±0.06$\downarrow$</td>
<td>3.38±0.41</td>
<td>2.73±0.66$\downarrow$</td>
</tr>
<tr>
<td>10</td>
<td>30.4±4.88</td>
<td>18.90±4.57$^{**}\downarrow$</td>
<td>20.63±1.76</td>
<td>18.23±1.27$\downarrow$</td>
<td>16.32±2.82</td>
<td>14.68±4.47$\downarrow$</td>
</tr>
<tr>
<td>11</td>
<td>11.79±3.46</td>
<td>5.96±1.46$^{**}\downarrow$</td>
<td>17.25±0.88</td>
<td>15.94±0.95$\downarrow$</td>
<td>11.26±1.88</td>
<td>10.56±2.58$\downarrow$</td>
</tr>
<tr>
<td>12</td>
<td>3.47±0.42</td>
<td>2.92±0.28$^*\downarrow$</td>
<td>5.72±0.28</td>
<td>5.07±0.40$^{**}\downarrow$</td>
<td>3.44±0.40</td>
<td>3.08±0.52$\downarrow$</td>
</tr>
<tr>
<td>13</td>
<td>4.93±0.27</td>
<td>4.36±0.38$^\downarrow$</td>
<td>5.38±0.33</td>
<td>4.98±0.17$^{***}\downarrow$</td>
<td>4.27±0.40</td>
<td>3.81±0.73$\downarrow$</td>
</tr>
<tr>
<td>14</td>
<td>1.18±0.14</td>
<td>0.99±0.12$^{**}\downarrow$</td>
<td>2.58±0.19</td>
<td>2.37±0.18$\downarrow$</td>
<td>1.07±0.12</td>
<td>1.01±0.10$\downarrow$</td>
</tr>
<tr>
<td>15</td>
<td>1.43±0.12</td>
<td>1.11±0.13$^{**}\downarrow$</td>
<td>2.22±0.12</td>
<td>1.96±0.13$^{**}\downarrow$</td>
<td>1.21±0.10</td>
<td>1.10±0.11$\downarrow$</td>
</tr>
<tr>
<td>16</td>
<td>3.88±0.49</td>
<td>3.15±0.44$^*\downarrow$</td>
<td>5.93±0.30</td>
<td>5.41±0.30$^{**}\downarrow$</td>
<td>3.33±0.28</td>
<td>3.15±0.34$\downarrow$</td>
</tr>
<tr>
<td>17</td>
<td>1.59±0.12</td>
<td>1.53±0.08$\downarrow$</td>
<td>2.10±0.14</td>
<td>2.07±0.06$\downarrow$</td>
<td>3.17±0.35</td>
<td>2.95±0.26$\downarrow$</td>
</tr>
<tr>
<td>18</td>
<td>2.36±0.21</td>
<td>1.85±0.25$^{**}\downarrow$</td>
<td>4.94±0.29</td>
<td>4.59±0.12$\downarrow$</td>
<td>2.28±0.07</td>
<td>2.17±0.08$^*\downarrow$</td>
</tr>
<tr>
<td>19</td>
<td>1.62±0.14</td>
<td>1.31±0.12$^{**}\downarrow$</td>
<td>1.54±0.10</td>
<td>1.38±0.06$^{**}\downarrow$</td>
<td>1.94±0.11</td>
<td>1.81±0.09$^*\downarrow$</td>
</tr>
<tr>
<td>20</td>
<td>0.27±0.05</td>
<td>0.24±0.06$\downarrow$</td>
<td>0.44±0.04</td>
<td>0.41±0.03$\downarrow$</td>
<td>0.41±0.04</td>
<td>0.39±0.02$\downarrow$</td>
</tr>
<tr>
<td>21</td>
<td>0.14±0.02</td>
<td>0.10±0.03$^*\downarrow$</td>
<td>0.20±0.01</td>
<td>0.17±0.01$^*\downarrow$</td>
<td>0.11±0.01</td>
<td>0.10±0.01$\downarrow$</td>
</tr>
<tr>
<td>22</td>
<td>0.09±0.01</td>
<td>0.02±0.05$^*\downarrow$</td>
<td>0.06±0.01</td>
<td>0.04±0.01$\downarrow$</td>
<td>0.01±0.00</td>
<td>0.01±0.00$\downarrow$</td>
</tr>
</tbody>
</table>
Table 3.10. The changes in the band frequency values of the control and simvastatin treated EDL, DIA and SOL spectra in 1850-850 cm\(^{-1}\) region. The values are the mean ± Standart Deviation for each sample. The degree of significance was denoted as \(p<0.05^*, p<0.01^{**}\).

<table>
<thead>
<tr>
<th>Band No</th>
<th>Control EDL (n=8)</th>
<th>Sim. Tr. EDL (n=7)</th>
<th>Control DIA (n=9)</th>
<th>Sim. Tr. DIA (n=8)</th>
<th>Control SOL (n=9)</th>
<th>Sim. Tr. SOL (n=9)</th>
</tr>
</thead>
<tbody>
<tr>
<td>9</td>
<td>1742.94±0.46</td>
<td>1746.41±0.92 <strong>↑</strong></td>
<td>1742.60±1.77</td>
<td>1743.26±1.43 †</td>
<td>1744.28±1.30</td>
<td>1745.34±1.11↑</td>
</tr>
<tr>
<td>10</td>
<td>1655.13±0.52</td>
<td>1656.40±0.58 <strong>↑</strong></td>
<td>1636.32±1.25</td>
<td>1637.26±1.01 †</td>
<td>1656.77±1.11</td>
<td>1657.20±0.63↑</td>
</tr>
<tr>
<td>11</td>
<td>1541.38±0.31</td>
<td>1542.24±0.47 <strong>↑</strong></td>
<td>1548.52±0.63</td>
<td>1549.15±0.69 †</td>
<td>1540.75±0.93</td>
<td>1541.25±0.60↑</td>
</tr>
<tr>
<td>12</td>
<td>1451.72±0.68</td>
<td>1452.86±0.55 *↑</td>
<td>1453.66±0.61</td>
<td>1453.49±0.55 †</td>
<td>1455.79±1.05</td>
<td>1455.27±1.42↓</td>
</tr>
<tr>
<td>13</td>
<td>1393.87±1.03</td>
<td>1394.49±0.45 ↑</td>
<td>1400.22±2.07</td>
<td>1398.56±2.05 †</td>
<td>1393.11±1.79</td>
<td>1392.66±1.24↓</td>
</tr>
<tr>
<td>14</td>
<td>1344.21±0.48</td>
<td>1344.32±0.49 ↑</td>
<td>1337.78±0.44</td>
<td>1338.11±0.50 †</td>
<td>1343.85±0.5</td>
<td>1344.03±1.07↑</td>
</tr>
<tr>
<td>15</td>
<td>1260.39±0.97</td>
<td>1263.44±2.44 *↑</td>
<td>1282.57±1.65</td>
<td>1281.84±1.25 †</td>
<td>1261.82±0.86</td>
<td>1260.77±1.00↓</td>
</tr>
<tr>
<td>16</td>
<td>1238.61±0.36</td>
<td>1239.03±0.26 *↑</td>
<td>1240.57±1.62</td>
<td>1240.41±0.58 †</td>
<td>1238.69±0.21</td>
<td>1238.46±1.58↓</td>
</tr>
<tr>
<td>17</td>
<td>1171.21±0.62</td>
<td>1170.57±0.29 ↓</td>
<td>1163.10±1.04</td>
<td>1166.06±2.80 †</td>
<td>1168.41±1.90</td>
<td>1169.58±1.75↑</td>
</tr>
<tr>
<td>18</td>
<td>1082.77±0.44</td>
<td>1085.15±2.10 *↑</td>
<td>1080.55±0.37</td>
<td>1079.31±0.65 **↓</td>
<td>1088.76±4.43</td>
<td>1086.84±2.61↓</td>
</tr>
<tr>
<td>19</td>
<td>1044.41±0.49</td>
<td>1045.23±0.70 *↑</td>
<td>1034.2±0.43</td>
<td>1034.04±0.59 ↓</td>
<td>1045.41±0.70</td>
<td>1043.45±1.05↓</td>
</tr>
<tr>
<td>20</td>
<td>977.31±0.96</td>
<td>979.04±2.17 **↑</td>
<td>972.35±1.04</td>
<td>972.21±0.36 ↓</td>
<td>975.60±1.70</td>
<td>972.17±3.01↓</td>
</tr>
<tr>
<td>21</td>
<td>930.11±0.80</td>
<td>931.24±0.74 *↑</td>
<td>934.85±0.95</td>
<td>933.60±1.98 ↓</td>
<td>929.26±1.48</td>
<td>927.60±3.47↓</td>
</tr>
<tr>
<td>22</td>
<td>874.67±0.43</td>
<td>875.41±0.23 **↑</td>
<td>876.19±0.90</td>
<td>875.25±0.64 ↓</td>
<td>874.49±0.59</td>
<td>874.26±1.25↓</td>
</tr>
</tbody>
</table>
The bands at 1656 and 1540 cm\(^{-1}\) are attributed to the amide I and II vibrations of structural proteins, respectively. The band centered at 1656 cm\(^{-1}\) (amide I) corresponds to the C=O stretching and the C-N stretching (% 60) vibrational modes weakly coupled with the N-H bending (% 40) of the polypeptide and protein backbone. The Amide I band was located at 1656 cm\(^{-1}\) for EDL and SOL muscles while it was located at 1636 cm\(^{-1}\) for DIA muscle. The band located at 1540 cm\(^{-1}\) (amide II) is assigned to the N-H bending (% 60) and the C-N stretching (% 40) modes of proteins (Melin et al., 2000; Takahashi et al., 1991; Wong et al., 1991; Haris and Severcan, 1999; Çakmak et al., 2003). This band was located at 1540 cm\(^{-1}\) for EDL and SOL muscles whereas it was placed at 1548 cm\(^{-1}\) for DIA muscle. The band areas of amide I and amide II bands decreased in the all simvastatin treated muscle types but more dramatically for EDL muscle (p<0.01**). For example, for EDL muscles the Amide I and Amide II band decreased as 38 % and 49.5 %, respectively which can be clearly in Figures 3.19 and 3.20.

**Figure 3.18.** Comparison of C=O Ester stretching band area value for control and simvastatin treated groups of EDL, DIA and SOL muscles. * shows significance of p<0.05.
Figure 3.19. Comparison of Amide I band area value for control and simvastatin treated groups of EDL, DIA and SOL muscles. **shows significance of p<0.01.

Figure 3.20. Comparison of Amide II band area value for control and simvastatin treated groups of EDL, DIA and SOL muscles. ** and * show significances of p<0.01 and p<0.05 respectively.
The shifts in the frequencies of amide I and amide II band to higher values were observed for all simvastatin treated muscle types but more significantly for EDL muscle (p<0.01**). For Amide I band, this shift was from 1655.13±0.52 to 1656.40±0.58 cm⁻¹ in EDL (p<0.01**) while this shift was insignificant in DIA and in SOL. For Amide II band, the shift was from 1541.38±0.31 to 1542.24±0.47 cm⁻¹ in EDL (p<0.01**) while this shift was found to be insignificant in DIA and in SOL.

As it can be seen from Figures 3.5, 3.9, 3.13 and Table 3.11, there was a decrease in the bandwidth of amide I band for all simvastatin treated muscles but this change is more profound for EDL muscle (p<0.05*).

Table 3.11. The changes in the bandwidth values of the control and simvastatin treated EDL, DIA and SOL spectra. The values are the mean ± Standard Deviation for each sample. The degree of significance was denoted as p<0.05*.

<table>
<thead>
<tr>
<th>Band Name</th>
<th>Control EDL (n=8)</th>
<th>Sim.Tr.EDL (n=7)</th>
<th>Control DIA (n=9)</th>
<th>Sim.Tr. DIA (n=8)</th>
<th>Control SOL (n=9)</th>
<th>Sim.Tr. SOL (n=9)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amide I</td>
<td>26.46±0.91</td>
<td>25.43±3.03 *↓</td>
<td>21.64±1.79</td>
<td>21.45±1.15 ↓</td>
<td>29.9±2.8</td>
<td>28.49±2.40 ↓</td>
</tr>
</tbody>
</table>

The intense band at 1452 cm⁻¹ is assigned to CH₂ bending mode of protein and lipids. A decrease in the area (Manoharan et al., 1993; Cakmak et al., 2003) of this band was observed for all simvastatin treated groups but more profoundly for EDL muscle (p<0.05*). As seen from Table 3.9, the frequency of this vibration significantly shifted to higher values in EDL muscle (p<0.05*), while it was shifted to lower values in the other muscle types.

A decrease in the area of the band at 1392 cm⁻¹ which is due to the COO⁻ symmetric stretching vibration of amino acid side chains and fatty acids (Jackson et al., 1998; Çakmak et al., 2003; Cakmak et al., 2006) was observed

88
for all the treatment muscles, which was more obvious for EDL muscle (p<0.05*).

The absorption bands of collagen are seen in a broad range in the spectrum. The main bands of collagen arise from peptide bond vibrations detected in amide A, I, II and III bands (Camacho et al., 2001). The amide III vibrations of collagen are seen in the spectral range between 1355 and 1167 cm\(^{-1}\) (Gough et al., 2003). The band located at 1343 cm\(^{-1}\) falls into this region of the Amide III vibrations, more specifically originates from the C-N and the C-C stretching and the N-H bending vibrations of collagen (Camacho et al., 2001, Gough et al., 2003; West et al., 2004). As it can be seen from Table 3.9, the area of this band located at 1343 cm\(^{-1}\) decreased in all the three types of muscles but more profoundly for EDL muscle (p<0.01*).

In the 1280-900 cm\(^{-1}\) frequency range, several macromolecules (e.g. polysaccharides and phosphate composing of macromolecules such as phospholipids and nucleic acids) give absorption bands (Melin et al., 2000; Cakmak et al., 2003). The relatively strong bands at 1261, 1236 cm\(^{-1}\) are mainly due to the asymmetric and the band of 1080 cm\(^{-1}\) is due to symmetric stretching modes of phosphodiester groups, which monitors the P=O bond present in the phosphate moieties (PO\(_4^2-\)) of nucleic acid backbone structures and phospholipids (Wong et al., 1991; Wang et al., 1997; Diem et al, 1999; Cakmak et al., 2003). The band located at 1260 cm\(^{-1}\) is due to non-hydrogen-bonded PO\(_2^-\) groups and the band located at 1238 cm\(^{-1}\) is due to more hydrogen-bonded PO\(_2^-\) groups (Rigas et al., 1990; Wong et al., 1991). There was a decrease in the area of 1261 cm\(^{-1}\) band in all treated muscles but more profoundly for EDL. This decrease was significant for EDL (p<0.01**) and DIA (p<0.01**) while insignificant for SOL. In addition, a decrease in the area of 1238 cm\(^{-1}\) band in treated muscles was observed which was more profound for EDL muscle (p<0.05*). The frequencies of these two bands shifted significantly to higher values in EDL muscles (p<0.05*) as it shifted to lower
values in DIA and SOL muscles.

The PO\textsubscript{2} symmetric stretching band is generally assigned at 1080 cm\textsuperscript{-1} (Lyman \textit{et al.}, 2001; Banyay \textit{et al.}, 2003). As seen from Table 3.9, a significant reduction in the area of this band was observed in all muscle types but more significantly for EDL muscle (p<0.05\ast). Furthermore, although a significant shift to higher values in the frequency of this band was observed in EDL muscle (p<0.05\ast), this shifting occurred to lower values for DIA (p<0.01\ast\ast) and SOL.

The DNA to protein ratio calculated by the ratio of the area of the PO\textsubscript{2} symmetric stretching band to the area of the amide II band was given in Table 3.12. As seen from the table, there was an increase in this ratio in all muscle types, more intensely for EDL muscle (p<0.05\ast).

\underline{Table 3.12.} The variations in the DNA to protein ratio of the control and simvastatin treated EDL, SOL and DIA muscles. The values are the mean ± Standard Deviation for each sample. The degree of significance was denoted as p<0.05\ast.

<table>
<thead>
<tr>
<th>Ratio of Peak Areas (DNA to protein)</th>
<th>Control EDL (n=8)</th>
<th>Sim.Tr.EDL (n=7)</th>
<th>Control DIA (n=9)</th>
<th>Sim.Tr. DIA (n=8)</th>
<th>Control SOL (n=9)</th>
<th>Sim.Tr. SOL (n=9)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PO\textsubscript{2} sym./ Amide II</td>
<td>0.21±0.07</td>
<td>0.32±0.07\ast\ast</td>
<td>0.287±0.01</td>
<td>0.289±0.01\ast\ast</td>
<td>0.20±0.03</td>
<td>0.21±0.05\ast\ast</td>
</tr>
</tbody>
</table>

The area of the band at 1170 cm\textsuperscript{-1} which is due to asymmetric stretching mode of the CO-O-C groups arising from ester bonds in cholesterol esters and phospholipids decreased for all muscle types but more profoundly for EDL muscle (Jackson \textit{et al.}, 1998, Toyran \textit{et al.}, 2007) (Table 3.9). The frequency of this band shifted to lower values in EDL muscle whereas it shifted to higher values for other muscles (Table 3.10).
The band at 1044 cm\(^{-1}\) is mainly assigned to the C-O stretching vibrations of polysaccharides especially glycogen. As seen from Figure 3.5, 3.9, 3.13 and Table 3.9, a decrease in the areas of this band was observed which was more dramatic in EDL muscle (p<0.05*). A more clear representation of the change in areas of all types of muscles is shown in Figure 3.21 (Melin et al., 2000; Toyran et al., 2006; Lyman and Murray-Wavelet, 1999).

The band centered at 976 cm\(^{-1}\) is generally assigned to symmetric stretching mode of dianionic phosphate monoester of cellular nucleic acids (Ci et al., 1999; Chiriboga et al., 2000; Cakmak et al., 2003) and ribose-phosphate main chain vibrations of the RNA backbone (Banyay et al., 2003, Tsuboi et al., 1969). There was a decrease in the area of this band in each treated muscle which was more dramatic for EDL. A shift to higher values in the frequency of this band was only observed in EDL muscle (p<0.05*) however, it was shifted to lower values for the other muscles.

![C-O stretching (Glycogen) Average Band Area](image)

**Figure 3.21.** Comparison of C=O stretching band area value for control and simvastatin treated groups of EDL, DIA and SOL muscles. * and ** show significances of p<0.05 and p<0.01 respectively.
The band centered at 929 cm$^{-1}$ arises from Z type of DNA (Banyay et al., 2003). A significant decrease in the area of this band was observed for both EDL and diaphragm muscle (p<0.05*). However this decrease was more profound for EDL. This decrease was found to be insignificant for SOL. In addition, the frequency of this band significantly shifted to higher values for EDL (p<0.05*).

The band centered at 873 cm$^{-1}$ originates from the vibrations of N-type sugars in the sugar phosphate backbone of nucleic acids (Banyay et al., 2003, Taillandier and Liquier, 1992). A decrease in the area of this band was observed for all muscles but more significantly for EDL muscle (p<0.05*). The frequency of this band shifted from 874.67±0.43 to 875.41± 0.23 (p<0.01**) in the frequency of this band was found in the EDL muscle.
CHAPTER 4

DISCUSSION

In the current study, we for the first time investigated and compared the effects of simvastatin on structure and functions of macromolecules in three types of skeletal muscle tissues, namely EDL, DIA and SOL. Statins are the largest class of drugs on the market and they widely used in the treatment of hypercholesterolemia due to the higher efficacy. Skeletal muscle accounts for around 45% of the total body weight and has a high metabolic rate and blood flow. As a consequence, it is highly exposed to drugs within the circulation. Therefore, it may be primarily and greatly affected from statins. Skeletal muscle is composed of different fiber types. Rat SOL muscle is largely composed of type I fibers (84% type I, 16% type IIa, 0% type IIb) having a characteristic of slow-contracting oxidative muscle whereas Rat EDL is largely composed of type II fibers (3% type I, 57% type IIa, 40% type IIb) having a fast-contracting glycolytic characteristic. On the other hand, rat diaphragm consists of a substantial proportion of type I fibers (42-39 % Type I, 24-25 % type IIa, 33-34 % type IIb) (Kilarski and Sjöström, 1990; Ariano et al., 1973, Delp et al., 1996, Kanbara et al., 1997).

EDL muscle is composed of fast twitch glycolytic fibers and utilizes glucose as energy source. Decreased food consumption may induce a reduction in the amount of glycogen, which is a glucose source. This decrease in glycogen level stimulates muscle fibers to use fatty acids for energy production (Smith et al., 1991). Statin treatment leads to a decrease in the level of fatty acids. Due to the decrease in the levels of energy sources in skeletal muscle, the EDL muscle can not contract properly. Therefore EDL muscle is affected firstly and profoundly from statin treatment.
The amide A band located between 3370-3330 cm\(^{-1}\) arising from the N-H and the O-H stretching modes of H\(_2\)O, proteins and glycogen. Since water was largely removed during sample preparation for FT-IR spectroscopy, its contribution to this band can be neglected, and therefore; the contribution can be considered to be only due to proteins and glycogen. The intensity and more accurately band area gives information about the concentration of related functional groups (Freifelder, 1982; Toyran et al., 2004; Toyran et al., 2006; Cakmak 2006). The reduction in the area of this band, which is the more profound in EDL muscle (p<0.05), suggests a decrease in the protein and glycogen content in simvastatin treatment. This reduction could have been resulted from the lack of the contribution from glycogen OH absorption (Melin et al., 2000, Cakmak et al., 2006). This decrease is as same as in the area of the band located at 1044 cm\(^{-1}\) (Lyman et al., 1999; Rigas et al., 1990; Cakmak et al., 2003, Cakmak et al., 2006). By histological staining method, Smith et al (1991) also showed a decrease in the glycogen level of type II fibers (EDL muscle) as result of statin treatment, which further support our findings.

As it can be seen from Figures 3.4 , 3.8 and 3.12, the C-H region (3050-2800 cm\(^{-1}\)) is populated by absorptions arising from the vibrations of olefinic=CH, -CH\(_2\) and -CH\(_3\) groups, most of which originate from lipids (Severcan et al., 2000; Severcan et al., 2003, Cakmak et al., 2006). The area of the CH\(_3\), the CH\(_2\) asymmetric and the CH\(_2\) symmetric stretching bands which are all due to lipid acyl chains, decreased in all three muscles, however, the most profoundly in EDL muscle(p<0.05). This suggests a reduction in the amount of lipids and a change in the composition of the acyl chains. This result was also supported by the decrease in the area of the CH\(_2\) bending (mainly lipids) at 1452 cm\(^{-1}\) and the COO\(^{-}\) symmetric stretching (fatty acids) at 1392 cm\(^{-1}\) (Severcan et al., 2000; Severcan et al., 2003). This prevalent decrease in lipid content may be due to an increase in skeletal muscle lipolysis or utilization of lipid sources because of statin treatment. Sato et al. (1991) have found that the activity of lipoprotein lipase increased in statin treated rat thigh muscle. The increase in
the activity of this enzyme shows an increase in the utilization of lipids as an energy source which might imply decrease in the area of lipid bands. On the other hand, by histological staining method, it has been shown that extensive lipid-filled vacuoles and lipid droplet accumulated in human muscle biopsies as a result of statin treatment (Phillips et al., 2002). In addition, by gas–liquid chromatography-mass spectrometry, Paiva et al. (2005) showed that the level of cholesterol and campesterol increased in human muscle tissue due to 80 mg/d simvastatin treatment. The lipid accumulation may be related to an increase in the receptor mediated uptake of cholesterol because the inhibition of cholesterol synthesis could lead to reduced synthesis of cholesterol in the muscle cells and the intake of cholesterol and other lipids from circulation increases in muscle tissue (Paiva et al., 2005). It has been reported that more and larger lipid droplets was observed in muscles of statin treated MCK-LPL mice than those in muscles of untreated mice and statin treated wild-type mice. The muscle cholesterol content in wild-type mice was also reported to be unchanged with statin treatment (Yokoyama et al 2007). However, it has been shown that the level of sarcolemmal lipids and mRNAs for membrane lipid associated proteins were unaffected by statin treatment (Draeger et al., 2006). As a result, there are some contradictory results about the effects of statin treatment on lipid composition of skeletal muscle. Our finding has shown a decrease in lipid content which contradicts with some of the studies stated above. These contradictory results may be due to the differences in the application dosage of statin. It is known that the adverse effects of statin are dose dependent. In the studies stated above low dose of statin approximately 1 mg/kg was applied but in our study high dose of statin about 50 mg/kg was administered.

The olefinic band (3010 cm\(^{-1}\)) arising from the CH stretching mode of the HC=CH groups, can be used as a measure of unsaturation in the acyl chains (Takahashi et al., 1991, Liu et al., 2002; Severcan et al., 2005). As seen from Table 3.4, the area of this band decreased in all simvastatin treated muscle
types, but the most profoundly for EDL muscle (p<0.01), indicating a decrease in the population of unsaturation in acyl chains of lipid molecules. This loss of unsaturation may be due to an increase in lipid peroxidation (Sills et al., 1994; Kinder et al., 1997). Simvastatin inhibits ubiquinone synthesis which also serves as antioxidant in both mitochondria and lipid membranes. A decrease in its synthesis may induce decreased free radical scavenging indicating an increase in the amount of ROS (Reactive Oxygen Species). Hence, lipid peroxidation was increased in simvastatin treated skeletal muscles due to the increased production of ROS (Baker and Tarnopolsky, 2001). It was reported that after stopping statin therapy, the level of 8-epi-PGF2a in serum, plasma and urine decreased, which is indicator of a significant in-vivo oxidation injury, supporting our result (Sinzinger et al., 2000). In addition, it has been shown that statin treatment decreased plasmalogens, which is associated with protection against oxidative damage. The decrease in the level of plasmalogens may be functionally linked to an increase in oxidative stress i.e. ROS (Laaksonen et al., 2006) which also supports our result.

In addition to the decrease observed in the area of olefinic band, there was a frequency shift to higher values for the olefinic band in EDL muscle (p<0.05). In the previous studies, the frequency shift to lower values was reported as to be an indication of an increase in the order of the system (Mantsch, 1984; Lopez-Garcia et al., 1993; Bizeau et al., 2000; Severcan et al., 2003). In our study the shift to higher values was observed in olefinic =CH stretching band representing the disordering of the unsaturated lipids in membranes of skeletal muscle tissue but more profoundly for EDL muscle. This disordering effect result from the increase in the dehydration effect which was also seen at C=O stretching band located at 1741 cm$^{-1}$ as a result of simvastatin treatment.

The frequency shifting of the CH$_2$ stretching vibrations can be used as a marker for the detection of lipid order (Liu et al. 2002; Mantsch, 1984; Severcan et al. 1997). In our study the frequency of the CH$_2$ asymmetric stretching band
shifted to lower values in simvastatin treated groups of three muscle types, but the shifting was the most profound in EDL muscle (p<0.05). This shifting demonstrates an increase in the order of the system, which indicates an increase in the number of trans conformers resulting in more rigid membrane structure. A possible explanation for the membrane rigidity is the presence of free radicals, and consequently the lipid peroxidation, which modifies lipid composition of the membrane. After oxidative stress, a decrease in the membrane unsaturated/saturated fatty acid ratio is detected with the formation of cross-linked lipid–lipid and lipid–protein moieties (Curtis et al., 1984; Levin et al., 1990; Niranjan and Krishnakantha, 2000). The altered unsaturated/saturated fatty acid ratio of membrane phospholipids evidently result in an increase in rigidity of membrane. Membrane lipid order parameter is required for the correct functioning ion channels. Therefore a more ordered membrane structure may alter the function of ion channels. It has been reported that statins impaired some membrane channels such as Na\(^+\)/K\(^+\) ATPase, Na\(^+\)/Ca\(^{2+}\), Na\(^+\)/Ca\(^{2+}\) ATPase pump and Na\(^+\) channel (Nakahara et al., 1994; Pierno et al., 1995; Awayda et al. 2004). Bandwidths of the same bands also give information about the dynamics of the system (Mantsch, 1984, Schultz and Naumann, 1991; Lopez-Garcia et al., 1993; Severcan et al., 2003; Severcan et al., 2005). The dramatic increase of the bandwidth of the CH\(_2\) asymmetric stretching band suggested an increase in the lipid fluidity for all the treated muscle samples but this increase is the most dramatic for EDL muscles (p<0.01) (Levin et al., 1990; Severcan et al., 1999, Toyran and Severcan, 2003; Korkmaz and Severcan, 2005). It is known that cholesterol level in membrane affects its fluidity. A decrease in cholesterol level might increase membrane fluidity (Vevera et al., 2005). It has been reported that statin affect skeletal muscle membrane fluidity through changes in cholesterol content (Baker and Tarnopolsky, 2001; Wortmann, 2002).
As seen from Table 3.10, the area of the C=O stretching vibration band (1741 cm$^{-1}$) which is due to the cholesterol esters and triglycerides diminishes in all muscles types but significantly for EDL muscle (p<0.05), implying a relative decrease in the concentration of ester groups belonging to triglycerides and cholesterol esters. This was also confirmed by the decline in the area of the CO–O–C asymmetric stretching (1170 cm$^{-1}$) (Nara et al., 2002; Voortman et al., 2002). In addition, the dramatic shifting of the 1741 cm$^{-1}$ band to higher frequency values in simvastatin treated muscle types (Table 3.9) indicates a difference in packing of ester groups within the tissue (Jackson et al., 1998) and decrease in the strength of the existing hydrogen bonds of the glycerol skeleton closer to the head groups or decrease in the number of hydrogen bonds i.e. dehydration (Korkmaz et al., 2005). The dehydration effect of simvastatin may result from the variation of dipole interaction between drug and lipid. The difference in packing may result from the decrease in the amount of unsaturated lipids which was more profound for EDL muscle (p<0.01) (Cakmak et al., 2006; Nara et al., 2002). This was further confirmed by the decrease in the area of the olefinic CH stretching absorption at 3015 cm$^{-1}$. It has been reported that statin treatment reduces the total cholesterol content of the human skeletal muscle cells while no change was observed in the triglyceride amount of the human skeletal muscle cells (Yamazaki et al., 2006). In addition, Yokoyama et al. (2007) showed that muscle cholesterol content was unchanged with statin treatment. On the other hand, an increase in the level of cholesterol in human muscle has been shown as a result of 80 mg/g simvastatin treatment (Paiva et al., 2005).

As it is clearly seen in Table 3.10, a decrease in the area of Amide I and Amide II bands was observed bands for all three muscles, but most profoundly for EDL muscle (p<0.01), indicating a decrease in total protein content of skeletal muscle after simvastatin treatment especially in fast contracting glycolytic muscle. This result was also supported by the decrease in amide A band (at 3330 cm$^{-1}$), amide B band (at 3072 cm$^{-1}$) and CH$_3$ symmetric stretching band
(at 2876 cm \(^{-1}\)) which are also due to proteins. A possible explanation is that the decrease in the serum levels of lipids and fatty acids triggers muscle to use amino acids from proteins as an energy source. It has been suggested that extreme protein degradation will damage the muscle if the situation is so hard and this causes the formation of acute myopathy and rhabdomyolysis (Motijima et al., 1998, Tchapda , 2005). Another explanation is that inhibition of mevalonate pathway by statins leads to the suppression of the prenylated (farnesylated or geranylated) small GTP proteins, such as Rho, Ras or Rac, which promote cell maintenance and cell survival and this leads to the apoptosis (Kaufmann et al., 2006). Moreover, Urso et al. (2005) showed that statin causes an increase in the number of genes involved in protein catabolism in the muscle which supports our finding.

The bandwidth of amide I band decreased significantly for EDL muscle (p<0.05) (Table 3.11). In addition, the frequency of the amide I and amide II bands shifted to higher values in all muscles but slightly higher for EDL muscle (p<0.01) (Table 3.10). This result was also consistent with the shifts of the frequencies of amide A band (at 3330 cm \(^{-1}\)), and amide B band (at 3072 cm \(^{-1}\)). These indicate conformational changes in tissue proteins (Haris and Severcan, 1999; Jackson et al., 1999). It was previously described that biochemical and/or genetic abnormalities of proteins or genes involved in skeletal muscle energy metabolism in more than 50% of patients is associated with statin-associated myopathy, supporting the changes in the synthesis and conformation of tissue proteins induced by statins (Vladutiu et al., 2006). In addition, it was reported a change in the action of protein folding in muscle as a result of statin treatment with exercise (Urso et al., 2005) which confirms statin induced structural changes in tissue proteins.

The band at 1392 cm \(^{-1}\) is due to the COO\(^{-}\) symmetric stretching vibrations of amino acid side chains and fatty acids (Jackson et al., 1998; Cakmak et al., 2003). The decrease in the area of this band indicates a decrease in the content
of amino acids and fatty acids, which is consistent with the other finding of our study stated above.

One of the important factors affecting the membrane structure and dynamics is the amount of proteins and lipids in the membranes (Szalontai et al., 2000). A precise lipid-to-protein ratio can be derived from the FTIR spectrum by calculating the ratio of the areas of the bands arising from lipids and proteins. The increase of this ratio especially in treated EDL muscle suggests that there was a much pronounced decrease in protein content when compared to the decrease in lipid content after simvastatin treatment (Table 3.10). Urso et al. (2005) stated that statin treatment with exercise considerably affected the Ubiquitin Proteasome Pathway which is tightly regulated and responsible for the recognition and degradation of the majority of proteins in skeletal muscle, which confirms our result.

The band located at 1344 cm\(^{-1}\) originates from the C-N and the C-C stretching and the N-H bending vibrations of collagen (Camacho et al., 2001; Gough et al., 2003; West et al., 2004). The 1365-1300 cm\(^{-1}\) spectral region contains bands assigned to plane-bending hydroxyl modes in saccharides (Cael et al., 1973; Carpenter and Crowe, 1989). Therefore, there may be contributions from saccharide molecules to this band. As seen from Table 3.9 and Figures 3.5, 3.9 and 3.13, a decrease was observed in the area of the amide III band located at 1343 cm\(^{-1}\) originating from the C-N and the C-C stretching and the N-H bending vibrations of collagen in all three muscles but the most profoundly for EDL muscle (p<0.01) (Camacho et al., 2001; Gough et al., 2003; West et al., 2004). This indicates a decrease in the amount of collagen in simvastatin treated muscles. It has been reported that pravastatin inhibited type IV collagen secretion in fetal calf serum due to suppression of mevalonate pathway products which plays a critical role in the proliferation of mammalian cells (Nishimura et al 1999). Moreover, Rombouts et al (2003) showed that simvastatin suppressed the collagen synthesis and cellular proliferation in hepatic satellite cells which also supports our results.
The PO\textsubscript{2} asymmetric and symmetric stretching bands located at 1239 cm\textsuperscript{-1} and 1080 cm\textsuperscript{-1} respectively, originating from the phosphate-stretching vibrations of nucleic acids and phospholipid head groups (Lyman et al., 2001; Banyay et al., 2003). These phosphate-stretching vibrations at 1300-1000 cm\textsuperscript{-1} monitor alterations in the quantity, conformational state, and the degree and position of phosphorylation of the nucleic acids in DNA, RNA and head-groups of the phospholipids (Mendelsohn and Mantsch, 1986; Dovbeshko et al., 2000; Kneipp et al., 2000). The frequency of the PO\textsubscript{2} asymmetric stretching mode is at 1240-1260 cm\textsuperscript{-1} when PO\textsubscript{2}\textsuperscript{-} groups are completely non-hydrogen-bonded, and approximately at 1220 cm\textsuperscript{-1} when PO\textsubscript{2}\textsuperscript{-} groups are completely hydrogen bonded (Rigas et al., 1990; Wong et al., 1991). So as the hydrogen bonding decreases, the frequency values shift to higher values in PO\textsubscript{2} asymmetric stretching vibration. In the absorption spectra of the skeletal muscle, in the region of the PO\textsubscript{2} asymmetric stretching band two bands were observed located at 1261 cm\textsuperscript{-1} and 1236 cm\textsuperscript{-1}. The band located at 1261 cm\textsuperscript{-1} is due to non-hydrogen-bonded PO\textsubscript{2}\textsuperscript{-} groups and the band located at 1236 cm\textsuperscript{-1} is due to more hydrogen-bonded PO\textsubscript{2}\textsuperscript{-} groups. The areas of these bands decreased more dramatically for EDL muscle (1261 cm\textsuperscript{-1} p<0.01, 1236 cm\textsuperscript{-1} p<0.05) as in comparison to the other two muscles as shown in Table 3.9. These results implied a decrease in the relative content of the nucleic acids in the treated tissues especially in EDL muscle (Ci et al., 1999). As seen from Table 3.10, the frequencies of these bands shifted to higher values in EDL muscles whilst it shifted to lower values in DIA and SOL muscles. The shifts to higher values in the frequencies of these bands indicate dehydration around the PO\textsubscript{2}\textsuperscript{-} functional groups of the nucleic acids and phospholipids while the shifts to lower values in the frequencies of these bands implies an increase in the hydration of the nucleic acid and phospholipids in membrane structures. The dehydration effect of simvastatin was also shown in the FTIR study of DPPC and DMPC multilamellar liposomes both gel and liquid-crystalline phases in the presence of simvastatin (Kocak et al 2007). All together these results suggest a change in DNA and RNA conformation. The decrease in the amount of nucleic acids
results from statin induced nuclear condensation and fragmentation through the activation of caspase 3 enzymes and it was also in agreement with other studies (Kubota et al., 2004). Schick et al (2007) reported that high dose simvastatin treatment lowered both mitochondrial and cellular DNA content in skeletal muscle.

The peak area ratio of the bands at 1080 cm$^{-1}$ (phosphate symmetric stretching-nucleic acid) and 1540 cm$^{-1}$ (amide II-protein) is often used to illustrate the change in the DNA and protein content of the cells (Mourant et al., 2003). A decrease in both protein and DNA content was observed in all muscles but the most profoundly for EDL muscle (p<0.05). The increase in this ratio implies protein content decreases more when compared with the DNA content (Table 3.12). This results supports that statin affects Ubiquitin Proteasome Pathway which is tightly regulated and responsible for the recognition and degradation of the majority of proteins in skeletal muscle.

The spectral region between 995-970 cm$^{-1}$ is assigned to the ribose-phosphate main chain vibrations of RNA (Banyay et al., 2003). The absorption bands originating from CC structure of the DNA backbone was assigned at 970-950 cm$^{-1}$ (Banyay et al., 2003). The band centered at 976 cm$^{-1}$ is generally assigned to symmetric stretching mode of dianionic phosphate monoester of nucleic acids (Ci et al., 1999; Chiriboga et al., 2000; Çakmak et al., 2003) and ribose-phosphate main chain vibrations of the RNA backbone (Banyay et al., 2003; Tsuboi et al., 1969). A decrease in the area of this band was observed in simvastatin treated muscle types which was more profound for EDL muscle (p<0.05), indicating a decrease in the nucleic acid, especially RNA content. This decrease suggests that the RNA production, therefore the protein synthesis decreases in simvastatin treated EDL muscle. This result supports the decrease in protein content mentioned earlier. The decrease in protein synthesis might have been caused by alterations in expression of nucleic acids which may be a result of any structural changes in nucleic acid structures.
The band centered at 929 cm$^{-1}$ results from Z type of DNA (Banyay et al., 2003; Liquier and Taillandier, 1996). A decrease in the area of this band which was more profound for EDL (p<0.05) implies a decrease in the area of DNA. Moreover, the frequency of this band shifted to higher values for EDL while it shifted to lower values for DIA and SOL. These results were consistent with the band centered at 873 cm$^{-1}$ originating from the vibrations of N-type sugars in the sugar phosphate backbone of nucleic acids, both DNA and RNA. This shows simvastatin affects DNA structure oppositely in these muscles which were first to be reported in this current study. This effect may be due to the changes in fiber composition of EDL, DIA and SOL muscles. These results support statin induced DNA degradation and structural alterations in DNA.

There are many histological and electrophysiological studies on the effects of statins on the skeletal muscle fibers (England et al., 1995; Schaefer et al., 2004, Draeger et al., 2006, Pierno et al., 1995, 1999, 2006; Gray et al., 2000; Liantonio et al., 2007; Inonue et al., 2003). It has been proposed that fast twitch muscle fibers are most sensitive to these drugs while slow twitch fibers are resistant to them. Moreover, it was reported that with the prolonged administration, all fiber types were ultimately affected. Our current study clearly showed that EDL muscle, which is composed of a high content of type II fibers, was more severely affected from statin treatment while SOL muscle which has high proportion of Type I fibers, was least affected from this drug in all the spectral parameters stated above.

During statin therapy, to detect statin induced myotoxicities, generally the level of serum creatine kinase enzyme level is measured. These myotoxicities are characterized by elevation in the level of Creatine Kinase in serum. However, there are many reports suggesting that the level of this enzyme was normal although patients suffer from myopathy which is one of the myotoxic effects of statin (Troseid et al., 2005; Philips et al., 2002). The adverse effects of statins on muscle are important for statin treated patients because these
drugs may cause even death due to the rhabdomyolysis. Therefore, ATR-FTIR and FTIR spectroscopy could be effective and useful tools to detect statin induced myotoxicities in muscle biopsies from statin treated patients in a very short time.
CHAPTER 5

CONCLUSION

The results of the present work indicated that significant alterations occurred in EDL, DIA and SOL skeletal muscle tissues after simvastatin treatment.

The detailed examination of the ATR-FTIR and FTIR spectra revealed the following observations:

There was a considerable decrease in both lipid and protein content of skeletal muscles, and these decreases were more easily observed for EDL muscle. It was also demonstrated for the first time in this study that the decrease in protein content was more remarkable when compared with the decrease in lipid content. The decrease in protein content suggested that protein degradation was increased or the synthesis of them was decreased in simvastatin treated muscles and this degradation changes from fast twitch to slow twitch fibers. While, the decrease in lipid content showed that lipolysis was increased which was reported in this current study for the first time.

Glycogen level was lower in simvastatin treated muscles, especially in EDL muscles.

In simvastatin treatment, muscle membrane lipids were more ordered when compared to control membranes, and this increase in order was the most pronounced in EDL muscle. The amount of unsaturated lipids decreased in treated tissues indicating the increased lipid peroxidation. Lipid peroxidation was found to be higher in EDL muscles. On the other hand, the disordering effect of simvastatin was observed for unsaturated lipids in EDL muscle.
Simvastatin treatment caused a decrease in the content of nucleic acids, especially RNA, and phospholipids in the membrane structures of skeletal muscles. It also caused a change in DNA and RNA conformation, possibly by alterations in the effect of hydrogen bonding in the DNA and RNA backbones.

The disordering effect of simvastatin for unsaturated lipids, change in DNA and RNA conformation, increase or decrease in hydrogen bonding of the DNA and RNA backbones were investigated for the first time in the present study.

In conclusion, in all of the spectral parameters investigated EDL muscle, which is composed of a high content of type II fibers, was found to be more severely affected from simvastatin treatment. This study was first to demonstrate the effect of simvastatin on the whole macromolecular content of skeletal muscle tissues, simultaneously. Moreover, it gives new insights to pathological studies for the detection of statin induced muscle degradation during the treatment of hypercholesterolemia.
REFERENCES


113


114


http://goldbamboo.com/topic-t1183-a1-6Cholesterol.html